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Preface
This dissertation is presented as three chapters including research from one
published research article. Chapter I provides background information and rationale for
this study, as well as a description of the three aims that accomplish the goals of the
study. Chapters II and III explain the research performed in completing the three aims of
the study. The data presented in chapters II and III and appendices A-E were published in
March of 2019 in Cell Reports (PMC6501849), entitled “GALNT3 Maintains the
Epithelial State in Trophoblast Stem Cells”. Chapter II contains the data supporting aim
one, entitled “GALNT3 is Important for Epithelial State Maintenance in Trophoblast
Stem Cells, Blastocyst Trophectoderm, and Human Mammary Epithelial Cells”. Chapter
III contains data supporting aims two and three, entitled “GALNT3 Mediated O-GalNAc
Glycosylation of E-cadherin Promotes the Epithelial State in Trophoblast Stem Cells and
Human Mammary Epithelial Cells”. Chapter IV includes conclusion for Chapters II and
III and also future directions of this work.
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Abstract
Deepthi Raghu. Ph.D. The University of Memphis. August 2019. GALNT3
Maintains the Epithelial State by Promoting O-GalNAc Modification of E-cadherin in
Trophoblast Stem Cells and Human Mammary Epithelial Cells. Major Professor:
Dr. Amy. N Abell, Ph.D.
O-GalNAc glycosylation is initiated in the Golgi by glycosyltransferases called
GALNTs. Proteomic screens identified >600 O-GalNAc modified proteins, but biological
relevance of these modifications has been difficult to determine. We have discovered a
conserved function for GALNT3 in trophoblast stem (TS) cells, blastocyst
trophectoderm, and human mammary epithelial cells (HMECs). Loss of GALNT3
expression in these systems reduces O-GalNAc glycosylation and induces epithelialmesenchymal transition. Further, Galnt3 expression is reduced in aggressive,
mesenchymal Claudin-low breast cancer cells. We show that GALNT3 expression
controls the O-GalNAc glycosylation of multiple proteins including E-cadherin in both
TS cells and HMECs. Loss of GALNT3 results in the intracellular retention of Ecadherin in the Golgi. Significantly, re-expression of GALNT3 in TS cells increases OGalNAc glycosylation and restores the epithelial state. Together, these data demonstrate
the critical biological role of GALNT3 O-GalNAc glycosylation to promote the epithelial
phenotype in TS cells, blastocyst trophectoderm, and HMECs.
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Chapter 1
Introduction
Specific Aims
Epithelial to mesenchymal transition (EMT) is a cellular program in which nonmotile epithelial cells convert to motile mesenchymal cells. In this morphogenetic
cellular process, epithelial cells lose cell-to-cell contact and apical-basal polarity with the
gain of mesenchymal morphology and invasive properties. EMT is critical in numerous
developmental processes and is reactivated in the adult tissues during organ fibrosis and
cancer metastasis. Murine trophoblast stem (TS) cells have been used to define the
molecular and epigenetic mechanisms regulating developmental EMT. Wild type TS
cells (TSWT) are epithelial with tight cell-cell adhesion, whereas TS cells lacking
MAP3K4 activity (TSKI4) express a mesenchymal-like phenotype. Galnt3 (UDP-GalNAc
transferase 3) gene expression is reduced in both TSKI4 cells and mesenchymal, Claudinlow (CL) breast cancer cells. This O-GalNAc glycosyltransferase, GALNT3, initiates Olinked glycosylation in the Golgi by transferring N-acetylgalactosamine (GalNAc) to the
hydroxyl groups of serine or threonine residues. Importantly, the function of GALNT3 is
to promote folding and localization of either membrane or secreted proteins. Aberrantly
glycosylated and misfolded proteins are either trapped in the Golgi or mislocalized to the
endoplasmic reticulum. With the exception of FGF23, substrates of GALNT3 are
unknown and undefined. Loss of function mutations in GALNT3 cause misfolding of
FGF23, a hormone required for phosphate homeostasis. Aberrant glycosylation of FGF23
causes a severe autosomal disorder, Hyperphosphatemic Familial Tumoral Calcinosis.
This disorder is characterized by increased phosphate levels and subcutaneous calcium
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deposits. Our preliminary data suggest that Galnt3 is reduced in all mesenchymal, CL
breast cancer cells relative to human mammary epithelial cells (HMEC). Further, we
observe decreased expression of Galnt3 in the mesenchymal TSKI4 cells relative to
epithelial TSWT cells. Based on our preliminary data, we predict that GALNT3 may be
responsible for the maintenance of the epithelial phenotype, and that loss of this gene is
associated with an invasive, mesenchymal phenotype in both TS cells and breast cells.
Our hypothesis is that GALNT3 regulates the folding and localization of proteins
that are important in the maintenance of the epithelial phenotype. The goal of this project
is to define the impact of GALNT3 dependent O-GalNAc glycosylation on
developmental EMT that is reactivated in breast cancer metastasis. We have addressed
this goal by examining the role of GALNT3 in the regulation of cellular phenotype in TS
cells, blastocyst trophectoderm, and HMECs. Alterations in the levels of GALNT3 in
both TS cells and breast cells impacts EMT/MET processes. In addition to the cultured
TS cells, we also examined the impact of loss of GALNT3 on EMT in the trophectoderm
of preimplantation blastocysts. Importantly, we observed that GALNT3 mediates the OGalNAc glycosylation of multiple proteins, including E-cadherin. For the first time, we
have defined the critical role of GALNT3 dependent O-GalNAc glycosylation in
promoting the epithelial state in both TS cells and HMECs.
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Background and Significance
Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is a morphogenetic cellular process
in which non-motile epithelial cells lose cell-to-cell contact and apical-basal polarity with
the gain of motile mesenchymal cells with front-back polarity (Kalluri and Weinberg,
2009). EMT is critical for numerous developmental processes and wound healing (Thiery
et al., 2009). Importantly, reactivation of EMT in the adult tissues occurs during organ
fibrosis and cancer metastasis (Chapman, 2011; De Craene and Berx, 2013). EMT is
reversible through mesenchymal-epithelial transition (MET), where motile, individual
mesenchymal cells convert to non-motile, tightly adherent epithelial cells (Esteban et al.,
2012; Mikkelsen et al., 2008). Sequential rounds of this reversible EMT process promote
the differentiation of specialized cell types and result in the formation of threedimensional structures of internal organs (Thiery et al., 2009). Developmental EMT
processes can be further classified as primary, secondary and tertiary EMT. In early
embryonic development, primary EMT occurs during gastrulation, where the cells from
the epiblast undergo EMT to form the mesoderm, endoderm, and ectoderm (Acloque et
al., 2009). In addition, epithelial neural crest cells also undergo primary EMT to form
neural tubes leading to the development of the central nervous system (Acloque et al.,
2009; Cheung and Briscoe, 2003; Cheung et al., 2005). Different subtypes of early
mesodermal cells are condensed to form transient epithelial structures including somites,
notochord, somatopleures, and splanchnopleures. These transient structures undergo
secondary EMT and differentiate to form specific cell types such as hematopoietic stem
cells, connective tissues, and secretary tissues (Buckingham et al., 2003). Tertiary EMT
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is poorly understood and the best studied example is formation of cardiac valves and the
endocardium of the heart (Nakajima et al., 2000).
Several molecular events occur during the initiation and completion of EMT.
These events include the loss of cell-cell adhesion proteins such as tight-junction
proteins, ZO-1 and Claudin-6, and adherens junction proteins including E-cadherin, acatenin, b-catenin, and d-catenin. Importantly, cells in EMT undergo reorganization of
actin cytoskeleton from epithelial cells with cortical actin to mesenchymal cells with
filamentous actin. In addition to morphological changes, cells lose the expression of
epithelial markers like E-cadherin (De Craene and Berx, 2013; Peinado et al., 2004;
Peinado et al., 2007; Yilmaz and Christofori, 2009). Cells gain mesenchymal marker
expression like Vimentin and N-cadherin and increase expression of EMT-inducing
transcription factors like TWIST1 and SNAI2 (Batlle et al., 2000; Cano et al., 2000;
Dong et al., 2013; Herranz et al., 2008; Peinado et al., 2004; Tong et al., 2012; Wheelock
et al., 2008; Yilmaz and Christofori, 2009). Most importantly, mesenchymal cells acquire
increased motility and/or invasiveness (De Craene and Berx, 2013; Kalluri and
Weinberg, 2009).
In addition to having an essential role during development, EMT is also
reactivated during tissue or organ fibrosis, and cancer metastasis. During fibrosis,
uncontrolled and constitutively active EMT results in continuous transition of epithelial
cells to myofibroblasts (Iwano et al., 2002; Mansour et al., 2017; Okada et al., 1996; Sato
et al., 2003; Tan et al., 2006; Zeisberg et al., 2007; Zeisberg et al., 2003). This sustained
EMT process results in increased deposition of extracellular matrix proteins leading to
high immune infiltration, persistent inflammation, and fibrosis (Iwano et al., 2002;
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Mansour et al., 2017; Okada et al., 1996; Sato et al., 2003; Tan et al., 2006; Zeisberg et
al., 2007; Zeisberg et al., 2003). During cancer metastasis, epithelial cancer cells undergo
EMT and convert to motile, invasive cells (Boutet et al., 2007; Byler et al., 2014; Byler
and Sarkar, 2014; Heerboth et al., 2014; Housman et al., 2014; Roche, 2018; Sarkar et al.,
2013). During cancer EMT, a subpopulation of metastatic cancer cells expresses both
epithelial and mesenchymal markers, suggesting that these cancer cells are in a partial
EMT state. The cells in partial EMT have increased expression of EMT inducing
transcription factors such as Snail, Twist, and Zeb family members (Saitoh, 2018). These
cancer cells are highly invasive and migrate either in clusters or as individual cells
leading to metastasis. Prat et al. (2010) examined microarray data from 337 patient breast
tumors and from 52 breast cancer cell lines (Hennessy et al., 2009; Herschkowitz et al.,
2007; Neve et al., 2006; Parker et al., 2009; Prat et al., 2010). Using these microarray
data from breast tumors and cell lines, they clustered different breast cancer subtypes
based on the gene expression (Prat et al., 2010; Prat and Perou, 2011). Breast cancer
subtypes were defined as Luminal A and B, Basal-like, HER-2 enriched, and Claudinlow (CL) breast cancers (Prat et al., 2010; Prat and Perou, 2011). Among these, CL breast
cancers have increased mesenchymal marker expression and show EMT characteristics
with stemness properties (Prat et al., 2010). The CL breast cancers are triple-negative
breast cancers that lack expression of estrogen, progesterone, and HER2 receptors. In
addition, CL breast cancers have complete absence of the tight junction proteins, Claudin
3/4/7, and the adherens junction proteins, E-cadherin and EpCAM. Importantly, CL
breast cancers are enriched in tumor-initiating factors such as CD44 and CD24. The
presence of these tumor-initiating factors enables cells to form tumors, a key feature of
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cancer stem cells. In addition, lack of estrogen receptors or HER2 receptors in the CL
breast cancer cells makes them unresponsive to targeted therapies such as tamoxifen and
lapatinib (Dias et al., 2017). Together, these data suggest that cancer cells that have
undergone EMT respond poorly to therapy, and thus these patients have low survival
rates. Therefore, defining the signaling mechanisms underlying EMT processes is
important for identifying new therapeutic strategies to treat EMT related diseases.
Glycosylation
Protein glycosylation plays a key role in both developmental EMT and EMT that
occurs in disease states. The majority of cell surface and secreted proteins undergo this
complex post-translational modification. Glycosylation occurs in either the endoplasmic
reticulum (ER) or the Golgi complex. During glycosylation, multiple glycoenzymes
mediate the attachment of carbohydrates to hydroxyl groups or amide groups of specific
proteins. This protein-oligosaccharide bonding promotes proper protein folding leading to
protein structural and functional stability (Shental-Bechor and Levy, 2008). Genetic
defects in the glycoenzymes or alterations in the glycosylation pathways result in aberrant
protein glycosylation (Yarema and Bertozzi, 2001). There are two major types of
glycosylation, N-linked and O-linked. These types of glycosylation are initiated in
different organelles and have distinct impacts on protein structure and function.
In the ER, the attachment of N-glycans to asparagine (Asn) residues on specific
proteins marks the initiation of N-glycosylation (Figure 1) (Stanley et al., 2015). The
consensus sequence begins with Asn followed by any amino acid except proline and then
serine or threonine residues (Asn-X-Ser/Thr) (Stanley et al., 2015). The biosynthesis of
N-glycosylation occurs primarily in the lumen of the ER membrane. The first step of
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synthesis includes a lipid-like molecule termed dolichol phosphate, which is followed by
“en bloc” transfer of 14 glycan sugars to proteins with the consensus sequence Asn-XSer/Thr (Figure 1). The specific glycans in the “en bloc” depend on the cell type and
physiological status of the cell. The most common N-glycan attachment to Asn is Nacetylglucosamine. Disorders associated with genetic defects in the N-glycans are termed
congenital disorders of glycosylation (CDG) (Freeze et al., 2015; Sparks and Krasnewich,
1993). These disorders are classified into two types, I and II. Type I patients have
incomplete N-glycan chains due to unoccupied sugars at the consensus sequence of the
protein (Freeze et al., 2015; Sparks and Krasnewich, 1993). In type II patients, N-glycan
structures are altered due to abnormal processing of glycoenzymes (Freeze et al., 2015;
Sparks and Krasnewich, 1993). Importantly, N-glycan biosynthesis and types of sugars
that are added to the protein depend on the cell type and the physiological status of the
cell such as development, differentiation or disease states.
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Figure 1: N-linked glycosylation occurs in both the ER and Golgi. Initiation of Nglycosylation occurs in the lumen of the ER and involves the transfer of glycan sugars
from the dolichol phosphate (DPP) onto Asparagine (Asn) residues of specific proteins.
Further, extension of glycans occurs in the Golgi as illustrated. Adapted from
http://biotechhelpline16.blogspot.com/2012/09/golgi-apparatus-golgi-apparatus-also.html
O-linked glycosylation occurs by the transfer of sugars onto hydroxyl groups of
serine or threonine residues of specific proteins (Van den Steen et al., 1998). There are
two main types of O-glycosylation that are distinguished by the specific sugar
transferred, N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc). OGlcNAc glycosylation is initiated by the transfer of GlcNAc to the hydroxyl groups of
serine and threonine residues of cytoplasmic or nuclear proteins. The consensus sequence
for O-GlcNAc glycosylation has not been defined. Two enzymes regulate protein OGlcNAc glycosylation, O-GlcNAc transferase catalyzes the transfer of O-GlcNAc
whereas O-GlcNAcase (N-acetylglucosamine hydrolase) removes O-GlcNAc from
proteins. This reversible O-GlcNAc glycosylation of proteins has been proposed to
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function as a response to nutrient and cellular stress, thus regulating processes including
protein transcription, signal transduction, and cellular metabolism (Bektas and
Rubenstein, 2011). Disruption of O-GlcNAc processes has been implicated in severe
diseases including metabolic disorders, cancer, and neurodegeneration (Yang and Qian,
2017). In contrast to O-GlcNAc glycosylation, O-GalNAc glycosylation occurs in the
Golgi and is initiated by the transfer of GalNAc onto serine and threonine residues of
membrane and secreted proteins (Figure 2) (Brockhausen et al., 2009). A large family of
glycoenzymes called polypeptide-N-acetylgalactosaminyl transferases (GALNTs) found
in the Golgi catalyzes the initiation of O-GalNAc glycosylation (Figure 2). GALNTs are
comprised of 20 members in humans and 19 in mouse that can be functionally redundant.
Although the consensus sequence for the addition of O-GalNAc has not been defined, it
has been suggested that the presence of a proline at the +3 or -3 position near serine or
threonine is preferred for O-GalNAc glycosylation (Bennett et al., 2012). The linkage of
a single GalNAc to the serine or threonine residues constitutes the simplest form called
Tn antigen (Bennett et al., 2012). Complex O-GalNAc glycans have core 1, 2, 3 glycan
structures added to the Tn antigen (Figure 2) (Bennett et al., 2012). The addition of core 1
O-GalNAc glycans to the Tn antigen forms T antigen. Both T and Tn antigens can be
terminated with sialic acid, termed sialylated-Tn (sTn) or T (sT) antigens. Increased
expression of short O-GalNAc glycans occurs in many tumors or poorly differentiated
cancers (Chia et al., 2016).
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Figure 2: O-GalNAc glycosylation occurs in the Golgi. The transfer of Nacetylgalactosamine (GalNAc) on Serine or Threonine (S/T) residues of specific proteins
is mediated by GALNTs and marks the initiation of O-glycosylation. The simplest form
of O-glycosylation is called Tn antigen. Addition of Core-1 glycans to the Tn antigen by
C1GALT1 enzyme forms the T antigen. These Tn and T antigens can also be terminated
with sialic acid forming the sialyl-Tn (sTn) antigen. The Core-1 glycans are further
elongated by the addition of fucose or galactose sugars or sialylLewis antigens. Overexpression of T, Tn, sTn and sialyl-Lewis antigens are found in
many cancers. Adapted from Chia et al. (2016).
O-GalNAc Glycosylation in Cancer
O-GalNAc glycosylation is the simplest form of O-glycosylation. Aberrant levels
of O-GalNAc glycans on proteins have been implicated during tumorigenesis and cancer
progression (Chia et al., 2016). There are two main mechanisms associated with altered
glycosylation in tumors, incomplete synthesis or neo-synthesis (Pinho and Reis, 2015).
Loss of initiating glycosyltransferases results in incomplete synthesis with increased short
O-GalNAc glycans and disrupted protein structures. In contrast, synthesis of
glycosyltransferases not normally expressed in a cell or tissue occurs in a neo-synthetic
process and can lead to new carbohydrate structures on proteins that may trigger a
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tumorigenic response (Pinho and Reis, 2015). In addition, mislocalization of GALNTs in
the ER also increases the presence of short O-GalNAc glycans on proteins(Bard and
Chia, 2016). Termination of proteins with sTn antigens are rarely found in healthy
tissues, but are abundantly present in cancers including pancreatic, stomach, colorectum,
and breast (Brockhausen, 1997; Julien et al., 2006; Munkley, 2016; Sewell et al., 2006).
The presence of sTn antigens in carcinomas is correlated with increased tumor size,
decreased cell-cell adhesion proteins, increased invasion, and poor prognosis (Kim and
Varki, 1997; Pinho et al., 2007; Pinho and Reis, 2015). In addition, loss of
glycosyltransferases or increased expression of sTn antigens has been associated with
cancer related EMT (Barkeer et al., 2018). Further, overexpression of short O-glycans on
MUC1 protein has been shown to cause cancer EMT in breast, ovary, prostate, and
pancreatic carcinomas (Aoki et al., 1998; Avichezer et al., 1998; Burdick et al., 1997;
Hough et al., 2000; Kufe, 2009, 2013; Maeshima et al., 1997; Medina et al., 1999; Strous
and Dekker, 1992; van Hof et al., 1996; Willsher et al., 1993; Zhang and Weinberg,
2018). Altered MUC1 glycosylation increases expression of EMT-inducing transcription
factors Snai1 and Zeb1 and decreases expression of a key epithelial marker, E-cadherin
(Ponnusamy et al., 2013). Together, structural alterations to the glycans due to absence of
the glycosyltransferases have been shown to be associated with cancer EMT (CarvalhoCruz et al., 2018; da Fonseca et al., 2016).
O-GalNAc Glycosylation in Development
The roles of O-GalNAc glycosyltransferases during cancer EMT are well defined,
but the functions of GALNTs in developmental EMT are poorly understood. Due to their
functional redundancies that may result in compensatory mechanisms, it has been
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difficult to identify the essential functions of GALNTs in developmental EMT. However,
studies in model organisms have identified specific roles for a few O-GalNAc
glycosyltransferases in development. In Drosophila, inactivating mutations in Pgant35A
causes disruption in the formation of the respiratory tract leading to lethality (Tian and
Ten Hagen, 2007). This phenotype exhibits EMT-like characteristics, including loss of
apical-basal polarity, distorted barrier formation, and decreased tight junction proteins
(Tian and Ten Hagen, 2007). In addition, loss of Pgant3 in Drosophila results in reduced
secretion of basement membrane components, leading to loss of cell-cell adhesion
(Zhang et al., 2008). In mice, loss of Galnt1 decreases secretion of basement membrane
components including Laminins (Tian et al., 2012). This increased intracellular
accumulation of basement membrane proteins results in decreased transcript levels of the
FGF pathway thus leading to reduced proliferation and growth of submandibular glands
(Tian et al., 2012). In Xenopus, knockdown of Galnt11 results in defects in left-right
patterning of the body (Boskovski et al., 2013). Together, these data suggest the
importance of O-GalNAc glycosylation in the maintenance of cell-cell adhesion proteins,
tight junction proteins, axial patterning, and secretion of basement membrane
components, thus regulating developmental EMT.
MAP3K4, a Mitogen Activated Protein Kinase Kinase Kinase
Mitogen activated protein kinase (MAPK) signaling pathways control key cellular
functions including proliferation, differentiation, survival, and apoptosis. MAPK
signaling is stimulated by external cues, and kinase activity depends on several factors
such as the kinetics of activation or inactivation, localization, and formation of protein
interaction complexes (Raman et al., 2007). These MAPK signaling pathways consist of
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evolutionarily conserved sequentially acting kinases whereby the MAPKKK/MAP3K
phosphorylates and activates MAPKK/MAP2K that phosphorylates and activates the
MAPK. Each component of the cascade consists of multiple family members. For
example, the MAP3K family of serine/threonine kinases is composed of 20 members.
These MAP3Ks selectively phosphorylate and activate different MAP2Ks. For example,
MAP3K4 phosphorylates and activates MAP2K3/4/6 and 7. These dual specific serine,
threonine and tyrosine MAP2Ks selectively phosphorylate and activate MAPKs. The
MAPK family is composed of 14 members that are subdivided into seven groups:
extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun amino-terminal kinase
1/2/3 (JNK 1/2/3), p38 (isoforms a, b, g, and d), ERK3/4, ERK5, ERK7, and nemo-like
kinase (NLK) (Chen et al., 2001; Cooper et al., 1982; Coulombe and Meloche, 2007;
Kyriakis and Avruch, 2001; Pearson et al., 2001). The MAPK subgroups are stimulated
by specific external cues. For example, the ERK1/2 subgroup is phosphorylated and
activated by MAP2K1 and MAP2K2 in response to growth stimuli (Kazlauskas and
Cooper, 1988; Ray and Sturgill, 1988). In contrast, environmental stress, bacterial
endotoxins, and proinflammatory cytokines stimulate both the JNK and p38 MAPKs
(Bogoyevitch et al., 2010; Cuadrado and Nebreda, 2010). These stresses induce the
phosphorylation of MAP2K4 and MAP2K7 that activates JNK, and the phosphorylation
of MAP2K3 and MAP2K6 that activates p38 (Derijard et al., 1995; Han et al., 1996;
Lawler et al., 1998; Stein et al., 1996). Further, MAP3K4 phosphorylates MAP2K4/7 and
MAP2K3/6. Importantly, MAP3K4 expression has been shown to be important during
developmental EMT, specifically in neural tube closure and skeletal patterning (Abell
and Johnson, 2005; Chi et al., 2005).
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MAP3K4 has several well-defined protein domains (Figure 3). The N-terminus
consists of growth arrest and DNA damage inducible 45 binding (GADD45) domain and
a kinase autoinhibitory domain. The C terminus includes a CDC42 and RAC interactive
binding (CRIB)-like domain and a 37 kDa kinase domain. Conformational changes of
these domains control MAP3K4 activity. In the inactive confirmation, MAP3K4 folds at
the CRIB-like domain and the N-terminal kinase-inhibition domain blocks the C-terminal
kinase domain (Mita et al., 2002). In the active confirmation, the N-terminal kinase
inhibition domain releases the C-terminal kin]ase domain, leading to dimerization of
MAP3K4 and phosphorylation of downstream MAP2Ks, MAP2K4/7 and MAP2K3/6
(Mita et al., 2002). GADD45 binds to the N-terminal regulatory domain, while Axin and
TNF receptor-associated factor 4 (TRAF4) bind to the kinase domain of MAP3K4 (Abell
et al., 2007; Abell and Johnson, 2005; Luo et al., 2003). Binding of these proteins
facilitates dimerization and activation of MAP3K4. TRAF4 binding to the MAP3K4
kinase domain promotes MAP3K4 dimerization and synergistic activation of JNK (Abell
and Johnson, 2005). Further, MAP3K4 can also bind to a scaffold protein, Axin, resulting
in JNK activation (Luo et al., 2003). Binding of GADD45 a, b, and g proteins to the Nterminal regulatory domain of MAP3K4 results in activation of p38 and JNK signaling
pathways (Mita et al., 2002). In contrast, binding of glycogen synthase kinase-3 beta
(GSK3b), a multifunctional serine or threonine kinase, to the MAP3K4 kinase domain
inhibits the activity of MAP3K4 (Abell et al., 2007). GSK3b phosphorylates the Nterminus of MAP3K4, thus preventing the dimerization of MAP3K4 (Abell et al., 2007).
Together, these studies have identified multiple binding partners of MAP3K4 that either
activate or inhibit the downstream signaling cascade.
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Figure 3: Diagram depicts the four protein domains of MAP3K4. Binding sites for
MAP3K4 interacting proteins are shown.
MAP3K4 expression is strongest during development with highest expression in
embryonic stem (ES) cells, trophoblast stem (TS) cells, neuroepithelium, and chorion
(Abell et al., 2005, Abell et al., 2009). Three mouse models have been created to
determine the physiological roles of MAP3K4. Two of these models have eliminated
MAP3K4 protein expression (Bogani et al., 2009; Chi et al., 2005; Warr et al., 2012). Chi
et al. created a targeted deletion of exon 3, resulting in the complete absence of MAP3K4
protein (Chi et al., 2005). The second model was generated using an ENU mutagenesis
strategy to identify genes important for sex determination. This strategy induced a single
nucleotide substitution of an A to T at position 1144 in MAP3K4. This mutation
introduces a premature stop codon at amino acid 382 of 1597 residues of the MAP3K4
protein. Western blotting suggests that the truncated MAP3K4 protein is unstable
(Bogani et al., 2009). Unlike the two models that eliminate MAP3K4 expression, the
Kinase-Inactive MAP3K4 (KI4) model was produced through a targeted mutation of the
active site lysine at position 1361 to arginine in the kinase domain of MAP3K4 (Abell
and Johnson, 2005). This mutation inactivates MAP3K4 phosphotransferase activity
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without affecting MAP3K4 protein expression. All three MAP3K4 mouse models show
embryonic and perinatal lethality due to multiple, severe developmental defects.
Consistent with the high expression of MAP3K4 in the developing neuroepithelium, all
three mouse models exhibit neural tube defects, including exencephaly and spina bifida
(*). These defects result from increased apoptosis of neuroepithelial cells, suggesting that
MAP3K4 might serve an anti-apoptotic function during neural development. Further,
MAP3K4 elimination models also display defects in sex determination (Bogani et al.,
2009; Warr et al., 2012). This disorder was due to reduced expression of a sex
determining gene Sry that caused the development of ovaries in a XY embryo.
Importantly, loss of MAP3K4 results in low SOX9 expression leading to growth
retardation of the gonads and disrupted testicular development (Bogani et al., 2009). The
KI4 mice have not been examined for changes in sex determination. In contrast to the
MAP34 elimination models, homozygous KI4 mice show defective skeletal patterning
including rib malformations and scoliosis. In addition, KI4 mice exhibit significant
hearing loss due to impairment in the mechanosensory hair cell development of the inner
ear and distorted hair cell differentiation (Haque et al., 2016). As previously stated,
MAP3K4 is highly expressed in the TS cells. Examination of homozygous KI4
conceptuses reveals defective decidualization and hyperinvasion, suggesting implantation
defects (Abell et al., 2009). Importantly, all of these defects, including neural tube,
skeletal and implantation defects, are due to perturbations in the EMT process. Together,
these data suggest that MAP3K4 is important for the regulation of normal developmental
EMT processes.
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Trophoblast Stem Cells as a Model for Developmental EMT
Murine trophoblast stem (TS) cells can be isolated from embryonic day (E) 3.5
preimplantation blastocysts and from E6.5 extraembryonic ectoderm. Preimplantation
(E3.5) blastocysts form a few days after conception and consist of approximately one
hundred cells. These preimplantation embryos are composed of two cell types: the inner
cell mass (ICM) and the outer trophectoderm (TE). Embryonic stem (ES) cells are
isolated from the inner cell mass, which differentiates to form the body. The
trophectoderm layer contains trophoblast stem (TS) cells, which differentiate to form the
placenta. In vivo, the inner cell mass of the blastocyst secretes FGF4 that binds FGFR2
receptors in the trophectoderm to maintain TS cell stemness (Simmons and Cross, 2005).
Similar to ES cells, the TS cells can be cultured indefinitely in the presence of specific
growth factors including FGF4 and conditioned media produced from mitotically
inactivated mouse embryonic fibroblasts (Tanaka et al., 1998). These cultured TS cells
demonstrate self-renewal properties and express stemness markers including Cdx2,
Eomes, Sox2, Elf5a, Tfap2c, and Esrrb (Auman et al., 2002; Avilion et al., 2003;
Donnison et al., 2005; Russ et al., 2000; Simmons and Cross, 2005; Strumpf et al., 2005).
Upon removal of FGF4, the TS cells differentiate into specific lineages that form mature
trophoblast subtypes of the placenta (Simmons and Cross, 2005). Differentiated subtypes
include spongiotrophoblasts, syncytiotrophoblasts, and giant cells (Simmons and Cross,
2005). There are several markers for differentiated trophoblasts including Gcm1, Tpbpa,
SynA, SynB, Prl3d1, Prl2C2, Ctsq, and Csh2 (Simmons and Cross, 2005).
Murine TS cells have been used to define the molecular and epigenetic
mechanisms regulating developmental EMT. The first EMT event occurs during
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blastocyst implantation. The epithelial TS cells in the trophectoderm undergo EMT to
become invasive giant cells that digest the uterine wall to establish placentation (Abell et
al., 2011). In culture, differentiation of TS cells induces EMT as characterized by loss of
the epithelial marker E-cadherin, gain in mesenchymal markers N-cadherin and vimentin,
and most importantly, acquisition of invasiveness (Abell et al., 2011). The wild-type TS
(TSWT) cells isolated from E3.5 preimplantation blastocysts are epithelial with tight cellcell adhesion and apical-basal polarity (Abell et al., 2011). The TS cells isolated from
KI4 (TSKI4) conceptuses exhibit a mesenchymal morphology with front-back polarity
(Abell et al., 2011). Embryos with inactivated MAP3K4 display developmental disorders
including neural tube, skeletal, and implantation defects that are due to perturbations in
EMT (Abell et al., 2009; Abell and Johnson, 2005). Undifferentiated TSKI4 cells show
key characteristics of EMT, including gain of mesenchymal morphology with increased
expression of mesenchymal markers Vim and Cdh2, and EMT-inducing transcription
factors Twist1 and Snai2 (Abell et al., 2011). In addition, TSKI4 cells display increased
invasiveness relative to TSWT cells. Importantly, TSKI4 cells maintain stemness properties
and multipotency (Abell et al., 2011). This work suggests that loss of MAP3K4 activity
in TS cells induces EMT in the context of stemness.
Reactivation of EMT occurs in epithelial cancer cells during cancer metastasis.
These metastatic cancers contain subset of cells that exhibit self-renewing and stemness
properties (Mani et al., 2008). Therefore, it has been hypothesized that EMT imparts
stemness in these cancer cell populations (Mani et al., 2008). Induction of EMT by
expressing constitutively active EMT inducing transcription factors such as Twist and
Snai in primary mammary epithelial cells results in a mesenchymal state with increased
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expression of stemness genes (Mani et al., 2008). Importantly, CL breast cancer cells
display a mesenchymal morphology and exhibit EMT and stemness characteristics
compared to all other breast cancer subtypes (Prat et al., 2010). CL breast cancers have
decreased expression of epithelial markers including E-cadherin, EpCAM, and keratins,
and increased expression of mesenchymal markers like Vimentin (Prat et al., 2010).
Importantly, CL breast cancers have increased expression of tumor initiating genes (Prat
et al., 2010). These CL breast cancer cells respond poorly to standard therapies (Prat et
al., 2010). Together, these data suggest that acquisition of EMT in the epithelial cancers
induces an invasive mesenchymal phenotype with increased expression of stemness and
tumor initiating genes.
Both the TSKI4 cells and CL breast cancer cells exhibit the properties of stemness
and EMT. DNA microarray data analysis from Abell et al. and Neve et al. found a
maximum overlap of gene expression profiles between TSKI4 cells and CL breast cancer
cells compared to other breast cancer subtypes (Abell et al., 2011; Neve et al., 2006).
Analysis of gene expression changes in TSKI4 cells and CL breast cancer cells revealed 31
shared down regulated genes, suggesting that these genes may be important for
maintaining an epithelial state (Abell et al., 2011). Lentiviral shRNA knockdown of 8 of
these 31 genes in the epithelial TSWT cells induced a mesenchymal morphology (Mobley
et al., 2017). Importantly, reduced expression of one of these eight genes, Galnt3 (UDPGalNAc transferase 3) in the TSWT cells resulted in the most dramatic mesenchymal
phenotype. Based on these data, we predicted that GALNT3 may be important for
epithelial state maintenance.
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GALNT3, an O-GalNAc Glycosyltransferase
GALNT3 initiates O-linked glycosylation in the Golgi by transferring GalNAc to
hydroxyl groups of serine or threonine residues on specific proteins (Bennett et al., 2012;
Topaz et al., 2004). Importantly, GALNT3 promotes protein folding and localization of
both membrane and secreted proteins (Beaman and Brooks, 2014). The structure of
GALNT3 includes three protein domains: a transmembrane domain, a glycosyltransferase
domain, and a carbohydrate-binding domain. Mutations or deletions in either the
glycosyltransferase domain or carbohydrate-binding domain have been implicated in
severe human pathologies (Esapa et al., 2012; Garringer et al., 2006; Garringer et al.,
2007; Ichikawa et al., 2009). For example, deletion of a 16 bp nucleotide region in exon 1
of GALNT3 results in a frameshift mutation leading to a premature stop codon in the
protein. This GALNT3 protein lacks activity due to the deletion of the
glycosyltransferase domain (Garringer et al., 2006). The absence of GALNT3 activity
results in misfolding of FGF23, a hormone controlling the phosphate homeostasis,
leading to a severe autosomal disorder called hyperphosphatemic familial tumoral
calcinosis (HFTC) (Topaz et al., 2004). This disease is characterized by increased serum
phosphate levels and calcium deposits in the skin and subcutaneous tissues (Topaz et al.,
2004). The role of GALNT3 is well established in a disease state such as tumoral
calcinosis (TC). GALNT3 has also been implicated in other diseases such as cancers.
Roles of GALNT3 in Cancer Progression
Expression levels of GALNT3 correlate with the differentiation state of cancer.
GALNT3 is strongly expressed in well differentiated cancers including pancreas, colon,
stomach, and breast adenocarcinoma (Sutherlin et al., 1997). Poorly differentiated
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mesenchymal pancreatic cancers have reduced endogenous Galnt3 levels relative to
moderately/well differentiated pancreatic cancers (Maupin et al., 2010). Reduction of
GALNT3 expression in well differentiated pancreatic cancers results in a poorly
differentiated cancer phenotype displaying a mesenchymal morphology with increased
invasiveness (Maupin et al., 2010). Pancreatic cancers with reduced Galnt3 expression
display increased EMT characteristics. Together, these data suggest that reduced Galnt3
expression is associated with a poorly differentiated EMT-like state (Maupin et al.,
2010). These findings are supported by work from Chugh et al. who showed that loss of
GALNT3 in the moderately/well differentiated pancreatic cancers induces EMT with
increased expression of Tn and T antigens. These changes in glycosylation may be due to
a compensatory mechanism mediated by the expression of other Galnts (Chugh et al.,
2016). Importantly, knockdown of Galnt3 in a specific moderately/well differentiated
pancreatic ductal adenocarcinoma, S2-013 cells, results in decreased proliferation and
induces apoptosis. This phenotype maybe explained through the differential glycosylation
of a GALNT3 specific substrate called GNAT-1, a membrane associate 3-subunit
guanine nucleotide-binding protein. Loss of GALNT3 in S2-013 cells results in reduced
the glycosylation of GNAT1, and altered protein conformation of the protein. siRNA
knockdown of Gnat1 in S2-013 cells also results in a phenotype similar to the loss of
GALNT3 (Taniuchi et al., 2011). Galnt3 expression has also been associated with poor
prognosis and low survival rates in patients with lung adenocarcinomas and gastric
cancers (Gu et al., 2004; Onitsuka et al., 2003). Patients with moderately/well
differentiated lung adenocarcinomas and gastric cancers have better survival rates relative
to low GALNT3 expressing poorly differentiated cancers (Gu et al., 2004; Onitsuka et
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al., 2003). In addition, the secretory cells including bronchial epithelial cells, alveolar
cells, and bronchial gland cells have endogenous expression of GALNT3. Loss of
GALNT3 in these tissue types is associated with decreased Ki67 staining, a proliferation
marker (Dosaka-Akita et al., 2002). In contrast to pancreatic, lung, and gastric cancers,
GALNT3 expression is increased in poorly differentiated ovarian cancers. shRNA
knockdown of Galnt3 in the A2780 ovarian cancer cells results in decreased migration,
invasion and proliferation. This phenotype in A2780 ovarian cancers was explained
through the differential glycosylation of MUC1 (Wang et al., 2014). Together, these data
suggest that the functional consequences of GALNT3 expression depend on cancer cell
type, grade of cancer, morphology, and most importantly expression of protein substrates.
Roles of GALNT3 in Development
Although the role of GALNT3 in cancers has been well defined, the functional
role of GALNT3 in development is restricted to a pathological disorder, TC (Balin et al.,
2012). Importantly, patients with TC have increased phosphate levels and subcutaneous
depositions of calcium associated with painful skin ulcerations and secondary infections
in bone (Ichikawa et al., 2009). Mutations in GALNT3, FGF23, and Klotho factors each
induce TC. To examine the role of GALNT3 in TC, Ichikawa et al. created a GALNT3
deficient mouse model. Although deletion of the Galnt3 gene results in decreased intact
FGF23 secretion and hyperphosphatemia, there was no visible evidence for calcifications
(Ichikawa et al., 2009). Interestingly, there were sex specific phenotypic differences,
where male mice show infertility, growth retardation, and increased bone mineral density
(Ichikawa et al., 2009). In addition to these mouse models with deletion of GALNT3,
ENU mutagenesis was used to create mice with a mutation in GALNT3 at Tryptophan
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position 589 to Arginine in the carbohydrate binding domain. These mice called TCAL
(Tumoral CALcinosis) displayed a TC phenotype characterized by hyperphosphatemia,
subcutaneous calcium deposits, and hyperostosis (Esapa et al., 2012). The TCAL male
mice also showed infertility with decreased sperm count similar to the GALNT3 deletion
mice (Esapa et al., 2012). Together, the GALNT3 deletion and/or mutant mouse models
were created to better understand TC. However, the associated developmental defects
occurring in these GALNT3 mouse models remain poorly studied.
Epigenetic Regulation of Galnt3 Expression
Although GALNT3 expression is altered in TS cells and CL breast cancers, the
mechanisms controlling the expression of Galnt3 gene during development and cancer
EMT are undefined. As previously described, MAP3K4 is an important regulator of
developmental EMT processes in TS cells (Abell et al., 2009; Abell and Johnson, 2005).
This kinase, activates CBP, a histone acetyltransferase, to promote acetylation of specific
histones H2A and H2B on the promoters of key epithelial genes (Abell et al., 2011).
Importantly, loss of MAP3K4 activity in the TSKI4 cells decreases CBP activity and
increases the expression and activity of a histone deacetylase, HDAC6 (Mobley et al.,
2017). MAP3K4-dependent HDAC6 expression and activity lead to the deacetylation of
the promoters of many epithelial proteins, thus inducing EMT. Both TSKI4 cells and CL
breast cancer cells have decreased H2BK5 acetylation (Abell et al., 2011). Using antiH2BK5Ac antibody chromatin immunoprecipitation coupled to sequencing, we identified
a significant list of genes that are predicted to regulate EMT (Mobley et al., 2017).
Among the list, we found 1817 genes that displayed decreased H2BK5Ac in the TSKI4
cells. Further, using RNA sequencing data for TSWT, TSKI4 and TSKI4 cells with HDAC6
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knockdown we found that 2624 transcripts were reduced in TSKI4 cells (Mobley et al.,
2017). Altogether, comparison of the genes in H2BK5Ac ChIP sequencing and RNA
sequencing data revealed 514 genes that were MAP3K4, HDAC6 and H2BK5Ac
dependent. Importantly, eight of 31 shared genes between TSKI4 and CL breast cancer
cells were also present in the 514 gene list. Among these eight genes, Galnt3 was one of
the top candidate genes. Based on these data, we predict that MAP3K4, HDAC6, and
H2BK5Ac may epigenetically regulate Galnt3 expression.
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Specific Aim 1: Examine the role of GALNT3 in regulating EMT in trophoblast stem
cells, blastocyst trophectoderm, and human mammary epithelial cells.
Our preliminary data show that Galnt3 expression is reduced in both TSKI4 cells
and CL breast cancer cells that display characteristics of stemness and EMT. Based on
these preliminary findings, we predict that Galnt3 is important in the maintenance of the
epithelial phenotype. Here, we investigate the role of Galnt3 on EMT in the blastocyst
trophectoderm, TS cells and human mammary epithelial cells (HMECs). Lentiviral
shRNA knockdown of GALNT3 in TSWT cells induces a mesenchymal phenotype,
decreasing epithelial marker expression and increasing the expression of mesenchymal
markers and EMT-inducing transcription factors. Importantly, loss of GALNT3 promotes
invasiveness. Further, lentiviral re-expression of GALNT3 in the TSKI4 cells restores the
epithelial state, thus inducing MET. In the mesenchymal TSKI4 cells, re-expression of
GALNT3 increases the expression of epithelial markers, decreases mesenchymal marker
expression, and importantly decreases invasiveness. These data suggest that GALNT3
regulates EMT in cultured TS cells. In addition, we wanted to examine the impact of loss
of Galnt3 on EMT in the blastocyst trophectoderm. Lentiviral shRNA knockdown of
Galnt3 in the preimplantation blastocyst trophectoderm induces early attachment and
outgrowth. Since EMT is reactivated during cancer metastasis, we examined the role of
GALNT3 in breast cancer EMT. Mesenchymal CL SUM159 breast cancer cells have
decreased Galnt3 expression relative to HMECs. Importantly, shRNA knockdown of
Galnt3 in HMECs induces a mesenchymal state. Together, these data led to the
hypothesis that GALNT3 is important for the epithelial state maintenance. Further, we
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hypothesized that GALNT3 might promote the O-GalNAc glycosylation of key proteins
important for epithelial state maintenance.
Specific Aim 2: Examine the impact of GALNT3 on O-GalNAc glycosylation levels in
trophoblast stem cells, blastocyst trophectoderm, and human mammary epithelial cells.
GALNT3 is a key O-GalNAc glycosyltransferase that catalyzes the addition of OGalNAc on serine or threonine residues of specific proteins. To measure O-GalNAc
glycosylation levels, we used a lectin called Vicia-Villosa Lectin (VVL) that specifically
binds to O-GalNAc modified proteins. Using this approach, we examined total OGalNAc glycosylation of proteins with altered expression of GALNT3 in both TS cells
and HMECs. O-GalNAc glycosylation is reduced in TSKI4 cells and CL SUM159 cells
lacking GALNT3 relative to TSWT cells and HMECs respectively. shRNA knockdown of
Galnt3 in TSWT cells and HMECs reduced O-GalNAc glycosylation. In addition, reexpression of GALNT3 in the TSKI4 cells and CL SUM159 breast cancer cells increases
total O-GalNAc glycosylation. To measure the cell surface and intracellular localization
of O-GalNAc glycosylated proteins, paraformaldehyde fixed and detergent permeabilized
immunostaining was performed, respectively. Immunofluorescence staining shows
significant cell surface localization of O-GalNAc glycosylated proteins in TSWT cells.
Reduced expression of GALNT3 in TSKI4 cells results in decreased total O-GalNAc
staining and O-GalNAc modified proteins are intracellularly retained in the Golgi. In
addition, loss of Galnt3 in the blastocyst trophectoderm results in decreased total OGalNAc glycosylation. Importantly, loss of GALNT3 in the TS cells does not induce the
compensatory expression of other GALNTs, suggesting that GALNT3 is the critical OGalNAc glycosyltransferase in TS cells. Together, these data led to our hypothesis that

26

GALNT3 controls the O-GalNAc glycosylation levels in TS cells and HMECs, thus
regulating the cellular phenotype. We further hypothesized that GALNT3 may promote
O-GalNAc glycosylation of epithelial proteins for the maintenance of an epithelial state.
Specific Aim 3: Identify EMT-related targets of GALNT3.
The data in Specific Aim 2 suggest that GALNT3 controls the O-GalNAc
glycosylation of multiple proteins in both TSWT cells and HMECs. Specifically, we
observe differential O-GalNAc glycosylation of a 130 Kda protein between TSWT and
TSKI4 cells. We identified the band as E-cadherin, a key epithelial protein. Importantly,
decreased GALNT3 expression in TSKI4 cells results in the intracellular retention of Ecadherin in the Golgi. In addition, re-expression of GALNT3 in TSKI4 cells increases OGalNAc glycosylation of E-cadherin, restoring the cell surface localization of E-cadherin
and the epithelial state. Further, we identified a threonine at position 63 in the
extracellular cadherin (EC) domain 1 of E-cadherin as the GALNT3 dependent OGalNAc glycosylation site. Together, this aim identifies a previously unknown target of
GALNT3. Importantly, O-GalNAc glycosylation of E-cadherin promotes the cell surface
localization of E-cadherin that is critical for the maintenance of the epithelial state.
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Chapter II
GALNT3 is Important for Epithelial State Maintenance in Trophoblast Stem Cells,
Blastocyst Trophectoderm, and Human Mammary Epithelial Cells
Introduction
Epithelial cell-cell adhesion is promoted by both proteins located at the cell
surface and those secreted into the extracellular matrix. These proteins are heavily
modified by the addition of carbohydrates controlling their localization, stability,
secretion, and proteolytic processing. Carbohydrate modifications occur in two ways: Nglycosylation, carbohydrates attached to amide groups of asparagine (N), and Oglycosylation, carbohydrates attached to hydroxyl groups of serine and threonine (S/T).
Proteomic screens suggest the majority of membrane and secreted proteins are
glycosylated, but the biological roles of these modifications remain mostly unknown.
Disruption of epithelial cell-cell adhesion occurs during epithelial to
mesenchymal transition (EMT) when epithelial cells with tight cell-cell adhesion and
apical-basal polarity convert to motile, mesenchymal cells with front-back polarity (Yang
and Weinberg, 2008). EMT is critical during mammalian development including
implantation, gastrulation, and neural crest formation (Thiery et al., 2009). Importantly,
EMT is reversible through a mesenchymal to epithelial transition (MET) in which motile,
mesenchymal cells are restored to a non-motile, epithelial state (Yang and Weinberg,
2008). In addition to its role in development, EMT is reactivated during tumor
progression and cancer metastasis. Aberrant O-glycosylation has been implicated in
cancer EMT (Chia et al., 2016). However, its role in developmental EMT is poorly
understood.
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In mammals, the first developmental EMT occurs in trophoblast stem (TS) cells
during implantation, where epithelial TS cells in the trophectoderm (TE) transition into
invasive giant cells (Thiery et al., 2009). Multipotent TS cells isolated from preimplantation blastocysts can be cultured indefinitely in the presence of FGF4 (Tanaka et
al., 1998). Upon FGF4 withdrawal, TS cells differentiate forming all the mature
trophoblast subtypes of the placenta (Tanaka et al., 1998). Wild-type TS (TSWT) cells are
epithelial with tight cell-cell adhesion and apical-basal polarity. In contrast, TS cells
isolated from mice with a targeted mutation that inactivates the kinase activity of
MAP3K4 (TSKI4 cells) exhibit a mesenchymal morphology with front-back polarity
(Abell et al., 2011). Embryos with inactivated MAP3K4 display developmental disorders
including neural tube, skeletal, and implantation defects that are due to perturbations in
EMT (Abell et al., 2009; Abell and Johnson, 2005). TSKI4 cells show key characteristics
of EMT, including reduced expression of epithelial markers like E-cadherin with
increased expression of mesenchymal markers Vim and Cdh2, and EMT-inducing
transcription factors Twist1 and Snai2, and promoted invasiveness (Abell et al., 2011).
Importantly, TSKI4 cells and mesenchymal Claudin-low (CL) breast cancer cells share
gene expression profiles and display properties of stemness and EMT (Abell et al., 2011).
Using DNA microarray data from Abell et al. (2011) and Neve et al. (2006), we
have identified a gene, Galnt3, whose expression is reduced in both TSKI4 cells and CL
breast cancer cells. UDP-GalNAc transferase 3 (GALNT3) is a member of a large family
of homologous genes called GALNTs, each displaying selective tissue and target
specificities (Beaman and Brooks, 2014). GALNTs initiate O-GalNAc glycosylation in
the Golgi through the transfer of N-acetylgalactosamine (GalNAc) onto S/T residues
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forming a Tn antigen on specific protein substrates (Bennett et al., 2012). Abnormalities
in the activity of GALNTs have been implicated in several pathologies. The role of
specific GALNTs in developmental EMT has been difficult to determine using GALNT
specific knockout mice, due in part to the potential functional redundancy of this large
family of glycosyltransferases. GALNT3 initiates O-GalNAc glycosylation, but its
function in stem cells is unknown. Reduced expression of GALNT3 in mesenchymal
TSKI4 cells relative to TSWT cells and in CL breast cancer cells relative to human
mammary epithelial cells (HMECs) suggested that GALNT3 may be important in
promoting an epithelial phenotype in these cell types.
Herein, we show that a MAP3K4/HDAC6/H2BK5Ac dependent gene, GALNT3
is a key regulator of EMT. shRNA knockdown of GALNT3 in TS cells, blastocyst
trophectoderm (TE), and HMECs results in the acquisition of the mesenchymal state. In
addition, loss of GALNT3 in TSWT cells results in the reduced epithelial marker
expression with gain of mesenchymal markers and EMT-inducing transcription factors.
Importantly, GALNT3 re-expression in the mesenchymal TSKI4 cells restores the
epithelial phenotype. Finally, loss of Galnt3 in the trophectoderm of the blastocyst results
in premature attachment and outgrowth. Together, our findings demonstrate that
GALNT3 is critical for the epithelial state maintenance in both the TS cells and HMECs.
Materials and Methods
Animals
Kinase-inactive MAP3K4 (KI4) mice having a point mutation of Lysine 1361 to
Arginine were created as described in Abell et al. 2005. These mice were maintained on a
pure 129/SvEv background as described in Abell et al. 2009. Because this mutation is

30

embryonic lethal, mice heterozygous for the mutation were used to maintain the line.
Mice were housed under standard animal house conditions. Wild-type mice used in these
experiments were generated from heterozygous crosses of the KI4 mice. Male and female
wild-type mice ages 2-6 months were used in timed breedings to generate blastocysts.
Female mice were euthanized 3.5 days post mating and blastocysts were isolated as
described under the heading Blastocyst analysis. The procedures and the project were
approved by and performed in accordance with the University of Memphis (Protocol
number 0825) Institutional Animal Care and Use Committee (IACUC) following NIH
guidelines.
Cell lines and culture conditions
Mouse extraembryonic TSWT cells (male) and TSKI4 cells (female) were isolated
as previously described from heterozygote crosses of mice with a targeted mutation in
MAP3K4 (K1361R) that inactivates MAP3K4 kinase activity (Abell et al., 2009). TS
cells were cultured in the absence of feeders in 30% TS media (RPMI 1640, 20% heat
inactivated fetal bovine serum (FBS), 1% penicillin and streptomycin (PS), 1% Lglutamine, 1% sodium pyruvate, and 100 µM β-mercaptoethanol) and 70% TS media
conditioned by mitotically inactivated mouse embryonic fibroblasts (MEF-CM). TS cells
were supplemented with FGF4 (37.5 ng/ml) and Heparin (1 µg/ml) to maintain their
stemness. In differentiation experiments, TS cells were cultured in TS media lacking
growth factors and MEF-CM. The human cell lines HMECs (adult female), SUM159
cells (adult female), and HEK293T (fetal female) were a kind gift from Dr. Gary Johnson
(UNC, Chapel Hill). HMEC cells were cultured in HuMEC ready medium (Thermo
Fisher Scientific) containing 5% FBS, 1% PS with HuMEC supplement and bovine
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pituitary extract. SUM159 cells were cultured in Ham’s F12 medium (Thermo Fisher
Scientific) supplemented with 5% FBS, 1% PS with 5 µg/ml insulin and 1 µg/ml
hydrocortisone. Dulbecco’s modified essential medium supplemented with 10% FBS and
1% PS was used to culture HEK293T cells. All cell lines were cultured in a humidified
atmosphere at 37ºC containing 7% CO2 (mouse) or 5% CO2 (human).
Plasmids
Lentiviral pLKO, TRCN0000055098 and TRCN0000055099 plasmids (Open
Biosystems) were used to create control and murine GALNT3 knockdown cells.
TRCN0000035456 and TRCN0000035458 plasmids (Dharmacon) were used to create
human GALNT3 knockdown cells. To create a human FLAG-GALNT3, we used
clone # 55179 BCII3565 in pDONR 223 (Vidal human ORFeome (Version 5.1)). These
inserts were cloned into a lentiviral FLAG tagged destination vector (Jordan et al., 2013)
using LR clonase II enzyme mix (Invitrogen).
Lentiviral production and infection
HEK293T cells (fetal female) were used to produce replication incompetent
lentivirus as previously described (Abell et al., 2011). Briefly, HEK293T cells were
cotransfected with either pLKO, shRNAs (Open Biosystems) or FLAG-GALNT3
constructs in combination with pMD2.G and psPAX2 (Addgene) using calcium
phosphate. After 48-72 hours, viral supernatants were harvested by ultracentifugation at
21,000 rpm for 2 hours at 4C and viral pellets were resupended in 100 µl of TS media
with growth factors or HuMEC media or Ham’s F12 media. Infection of TS cells was
performed as previously described (Abell et al., 2011). Transduced cells were selected
using puromycin (2 µg/ml).
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Real-time quantitative PCR
Isolation of RNA from TS cells was performed using RNeasy Plus minikit
(Qiagen). High-Capacity reverse transcription kit (Thermo Fisher Scientific) was used to
prepare cDNA from 3 µg RNA. The Bio-Rad CFX96 Touch qPCR system with iTaq
(Bio-Rad) was used to measure gene expression changes. Expression levels were
measured using 2−ΔΔCt method and were normalized to mouse Actb or human Gapdh or
human Tbp. Primers used are specified in Appendix E.
Western blot analysis
Whole-cell, cytoplasmic, and nuclear lysates of TS cells were harvested as
previously described (Abell et al., 2009; Abell and Johnson, 2005). Briefly, whole-cell
lysates were harvested in buffer A (20 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1
mM EGTA and 1% Triton X) with protease inhibitors (1 mM PMSF and 17 μg/ml
aprotinin) and phosphatase inhibitors (1 mM sodium vanadate and 1 mM sodium
fluoride). Cytoplasmic lysates were harvested in 0.5% Triton in 1X phosphate buffered
saline with protease and phosphatase inhibitors described above. Nuclear lysates were
harvested in RIPA buffer (buffer A, 0.1 mg/ml sodium dodecyl sulphate and 0.1 mg/ml
sodium deoxycholate) with protease and phosphatase inhibitors described above. Lysates
were probed with the indicated antibodies specified in the Appendix A.
Immunofluorescence staining
Immunostaining was performed as previously described (Abell et al., 2009).
Briefly, cells were cultured on glass coverslips for two or three days. Cells were fixed
with 3% paraformaldehyde in 1X PBS for 10 min and then washed three times with 1X
PBS. Cells were permeabilized with 0.1% Triton for 3 min. Cells were blocked with 10%
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fetal bovine serum for 1 hour at RT. Coverslips were incubated with primary antibody
overnight at 4C. Next, the cells were washed for 30 min and then incubated with DAPI
(0.1 µg/ml), Dy-Alexa 488 (1:500) (Thermo Fisher Scientific), Alexa 594 (1:250) (Cell
Signaling Technology) for one hour at RT. Coverslips were washed and mounted on
slides with mounting media (90% glycerol and 10% 1mM Tris pH 7.5). Coverslips were
imaged using an EVOS epifluorescence microscope or a Nikon A1 laser scanning
confocal microscope.
Immunofluorescence imaging
Immunofluorescence imaging was performed using Nikon A1 laser scanning
confocal microscopy and a 60X Plan Apochromat 1.4 numerical-aperture (NA) oil
objective with lasers at 408, 488 and 594 nm. Individual Z-stacks and the 2D images
were obtained by either Maximum Intensity Projection (MIP) or Extended Depth of Field
(EDF) for all wavelengths.
Blastocyst analysis
Wild-type blastocysts were isolated from timed matings of pure 129/SvEv males
with females in the pure 129/SvEv and 129/SvEv/C57B6 mixed backgrounds. Mid-stage
blastocysts were hatched by transfer into drops of Acid-tyrodes (Millipore Sigma) for two
min. The trophectoderm layer of the hatched, intact blastocysts was infected as
previously described (Georgiades et al., 2007). Briefly, 100 µl drops of lentiviruses
encoding shControl or shGalnt3 resuspended in KSOM-AA (Millipore Sigma) were used
to infect hatched blastocysts for 6 hours. Post infection, blastocysts were transferred into
KSOM-AA for 24 hours. Attachment of the blastocysts was assessed after transfer of
infected blastocysts into 70% TS medium supplemented with FGF4.
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For measurement of puromycin resistance gene expression, RNA was isolated
five days post infection from attached and differentiated trophoblast cells in shControl
and shGalnt3 using RNeasy micro kit (Qiagen). High-Capacity reverse transcription kit
(Thermo Fisher Scientific) was used to prepare cDNA. PCR reactions for puromycin
resistance gene encoded by the lentiviruses were performed. PCR products were run on a
2% agarose gels and imaged using Bio-Rad ChemiDoc.
Chromatin IP coupled to qPCR
ChIP was performed as previously described (Abell et al., 2011). Sonicated
samples were immunoprecipitated (IP) with 5 µg of anti-HDAC6 antibody (Cell
Signaling Technology) or 5 µg of anti-H2BK5Ac antibody (Abcam). The Bio-Rad
CFX96 Touch qPCR system with SsoFast (Bio-Rad) was used to measure promoter
enrichment. Primers used for ChIP coupled to qPCR (ChIP-PCR) are specified in
Appendix E.
H2BK5Ac ChIP-seq read density plot analysis
Anti-H2BK5Ac ChIP-seq data from database: GSE92426 aligned to the mm9
reference genome was visualized as in Mobley et al. using Easeq. Aligned data files
were deposited as Datasets and annotated using the mouse mm9 genome Geneset. The
FillTrack utility in Easeq software was used to display the read density relative to input at
the Galnt3 transcription start site + 20 kb. The units of the y-axis are normalized, binned
read counts calculated as specified in Lerdrup et al. (Lerdrup et al., 2016)
Transwell solute flux assay
Barrier assays were performed as previously described (Mobley et al., 2017).
Briefly, TS cells were plated in 24 well 0.4 µm pore size PET membrane Transwells

35

(TSKI4Gab cells) or polycarbonate membrane transwells (TSWTGsh cells) (Corning Life
Sciences). Cells were grown to confluence for three days and then dye diffusion was
measured using the Synergy H1MD plate reader (BioTek).
Invasion assay
Invasion assays were performed as previously described (Abell et al., 2011).
Briefly, TS cells were plated on growth factor reduced Matrigel coated 8 µM pore
transwell (TW) chambers. After 48 hours, invasion assays were terminated. Noninvading cells from the top of the TW were removed using swabs and 1X PBS washes.
Invasive cells at the bottom of the TW were fixed in 3% paraformaldehyde for 10 min
and stained with DAPI (2 µg/ml) for 30 min. Five 10X fields for each TW were imaged
using EVOS epifluorescence microscope. These images were manually counted, and
graphs were plotted using Prism7 (version 7.0, GraphPad Prism software).
Statistical methods
The statistical details of the experiments including statistical tests used, value of
n, and what n represents, can be found in the figure legends. A *p-value < 0.05, **pvalue < 0.01, ***p-value < 0.001, and ****p-value < 0.0001 were considered statistically
significant. Softwares used to calculate statistical analyses are detailed below.
For qPCR data, the Bio-Rad CFX Maestro software (version 3.0) was used to
perform a Student’s t test corrected for multiple comparisons. For all other statistics
shown, Prism7 (version 7.0, GraphPad software) was used to perform a Student’s t test
corrected for multiple comparisons.
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Breast cancer data statistical analysis
For the analysis of breast cancer cell line data from Neve et al., the molecular
subtypes were assigned by Prat et al. based on gene expression signatures. Of the 52 cell
lines analyzed, 49 were classified into molecular subtypes by hierarchical clustering by
Prat et al: 25 as luminal, 15 as basal-like, and 9 as claudin-low. Using the “stats” package
in “R”, the following analyses were performed on the 49 classified cell lines (Team,
2013). The significance of differences in expression of Galnt3 between luminal, basallike, and claudin-low subtypes was assessed using the Student’s t test with Bonferroni’s
correction for multiple comparisons (pairwise.t.test()). Linear regression analysis (lm())
was used to model the relationship between Galnt3 and Cdh1 gene expression across the
49 classified breast cancer cell lines.
Results
Loss of GALNT3 is associated with acquisition of the mesenchymal state
We previously demonstrated that TSKI4 cells lacking MAP3K4 kinase activity
exist in a metastable state, having reduced epithelial features and increased mesenchymal
characteristics while maintaining stemness (Abell et al., 2011). Unlike TSWT cells that
displayed an epithelial morphology with tight cell-cell adhesion and apical-basal polarity,
TSKI4 cells displayed a mesenchymal-like morphology with the loss of cell-cell adhesion
and gain of front-back polarity (Figure 4A). Similar to TSKI4 cells, CL breast cancer cells
display properties of both EMT and stemness (Abell et al., 2011). Unlike HMECs that
have an epithelial morphology, the CL breast cancer cell line SUM159 displayed a
mesenchymal morphology, consistent with the EMT features of CL breast cancer cells
(Figure 4B).
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Analysis of DNA microarray data from Abell et al. suggested that Galnt3
expression is reduced in TSKI4 cells relative to TSWT cells. Galnt3 transcript and protein
were reduced in TSKI4 cells relative to TSWT cells as measured by real time quantitative
PCR (qPCR) and Western blotting, respectively (Figures 4C and 4D). Induction of EMT
through differentiation of TS cells also decreased Galnt3 transcript levels (Figure 4E).
Examination of Galnt3 expression in the breast cancer cell line microarray dataset from
Neve et al. revealed that loss of Galnt3 expression was strongly associated with the CL
form of breast cancer (p < 0.0001) (Figure 4F). E-cadherin levels are lowest in the CL
form of breast cancer as compared to all other breast cancer subtypes (Prat et al., 2010).
Comparison of Cdh1 and Galnt3 expression in breast cancer cells from the Neve et al.
dataset showed that Galnt3 loss was associated with the loss of Cdh1 (p < 0.0001),
suggesting a strong correlation between Galnt3 and Cdh1 expression (Figure 4G). Galnt3
transcript and protein were reduced in mesenchymal SUM159 cells relative to epithelial
HMECs (Figures 4H and 4I). These data showed that GALNT3 expression was decreased
in both mesenchymal-like TSKI4 cells and CL breast cancer cells, suggesting that loss of
GALNT3 is associated with loss of the epithelial state in TS cells and CL breast cancer.
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Figure 4. Loss of GALNT3 correlates with the gain of a mesenchymal state. (A-B) Phase
microscopy images are representative of three independent experiments. Black bar
represents 100 µm. (C) Reduced Galnt3 transcripts in mesenchymal TSKI4 cells relative
to TSWT cells. qPCR data normalized to Actb are expressed as a fold-change relative to
TSWT cells and are the mean ± range of two independent experiments. (D) Western blots
are representative of three independent experiments. (N.S., Non-Specific). (E) Decreased
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Figure 4 (Continued)
Galnt3 transcripts with differentiation of TSWT cells by FGF4 withdrawal for the
indicated number of days. qPCR data normalized to Actb are expressed as a fold-change
relative to undifferentiated TSWT cells (0 day) and are the mean ± range of two
independent experiments. (F) Galnt3 expression is significantly reduced in Claudin-low
(CL) breast cancer cell lines. Luminal (Lum), Basal-like (BL), and CL breast cancer
subtypes. p value was calculated using Student’s t test and Bonferroni’s correction for
multiple comparisons. **** p-value < 0.0001. (G) Loss of Galnt3 is significantly
correlated with reduced Cdh1 levels. Plot shows the correlation between Galnt3 and
Cdh1 transcripts in breast cancer subtypes. Each “+” represents a specific breast cancer
line. p value was calculated using linear regression and 𝛽" 1 represents estimate of the
slope of linear regression line. (H) Galnt3 transcripts are reduced in mesenchymal
SUM159 cells relative to HMECs. qPCR data normalized to Gapdh are expressed as a
fold-change relative to HMECs and are the mean ± SEM of three independent
experiments. (I) Western blots are representative of three independent experiments. ***
p-value < 0.001, Student’s t test.
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Transcriptional regulation of Galnt3 expression by MAP3K4 and HDAC6
We have previously demonstrated that MAP3K4 inhibits HDAC6 expression and
activity (Mobley et al., 2017). HDAC6 induces EMT in TS cells by binding to the
promoters of epithelial maintenance genes, deacetylating histone H2BK5, and repressing
gene expression. RNA-seq data from Mobley et al. suggested that Galnt3 expression was
HDAC6 dependent. HDAC6 expression at both transcript and protein levels was elevated
in TSKI4 cells relative to TSWT cells (Figure 5A and 5B). HDAC6 protein was also
elevated in the nuclei of SUM159 cells relative to HMECs (Figure S1A). Knockdown of
HDAC6 in TSKI4 cells with a short hairpin RNA (shRNA) (TSKI4H6sh cells) reduced
HDAC6 transcript and protein and restored an epithelial morphology (Figure 5A-5C).
Galnt3 transcripts were increased in TSKI4H6sh cells relative to TSKI4 cells resulting in a
50% increase in GALNT3 protein (Figure 5D and 5E). These data suggested that HDAC6
inhibits the expression of Galnt3.
We predicted that HDAC6 regulates the expression of Galnt3 by directly binding
the Galnt3 promoter and deacetylating H2BK5. As measured by anti-HDAC6 chromatin
immunoprecipitation coupled to qPCR (ChIP-PCR), HDAC6 was enriched on the Galnt3
promoter in TSKI4 cells relative to TSWT cells (Figure 5F and Figure S1B). AntiH2BK5Ac ChIP-PCR and published ChIP-seq data from Mobley et al. showed reduced
H2BK5Ac on the Galnt3 promoter in TSKI4 cells relative to TSWT cells (Figure 5G and
5H and Figure S1C). Knockdown of HDAC6 in TSKI4 cells increased H2BK5Ac on the
Galnt3 promoter (Figure 5G and 5H). Similar to TS cells, anti-HDAC6 ChIP-PCR
showed enrichment of HDAC6 on the Galnt3 promoter in SUM159 cells relative to
HMECs (Figures S1D and S1E). Further, anti-H2BK5Ac ChIP-PCR showed a
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concomitant decrease in H2BK5Ac on the Galnt3 promoter in SUM159 cells (Figure
S1F). These data suggested that HDAC6 is bound to the Galnt3 promoter in
mesenchymal-like TSKI4 cells and CL SUM159 breast cancer cells, actively deacetylating
H2BK5 and repressing Galnt3 expression.
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Figure 5. Galnt3 expression is co-regulated by MAP3K4 and HDAC6. (A) Hdac6
transcripts analyzed by qPCR in TSWT cells and TSKI4 cells expressing control shRNA or
TSKI4 cells expressing Hdac6 shRNA (TSKI4H6sh) are shown. qPCR data normalized to
Actb are expressed as a fold-change relative to TSWT cells and are the mean ± SEM of
three independent experiments. (B) Western blots of whole cell lysates are representative
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Figure 5 (Continued)
of three independent experiments. (C) Knockdown of HDAC6 in TSKI4 cells restores an
epithelial morphology. Phase microscopy images are representative of three independent
experiments. Black bar represents 100 µm. (D) Hdac6 knockdown increases Galnt3
transcripts in TSKI4H6sh cells relative to TSKI4 cells. qPCR data normalized to Actb are
expressed as a fold-change relative to TSWT cells and are the mean ± SEM of five
independent experiments. (E) GALNT3 protein expression increases with knockdown of
HDAC6 in TSKI4H6sh cells. Western blots are representative of two independent
experiments. (F) Anti-HDAC6 ChIP-PCR shows increased HDAC6 enrichment on the
Galnt3 promoter in TSKI4 cells relative to TSWT cells. Data shown are the mean ± SEM of
four independent experiments. (G) Decreased H2BK5 acetylation on the Galnt3 promoter
in TSKI4 cells relative to TSWT cells as measured by anti-H2BK5Ac ChIP-PCR. Data
shown are the mean ± SEM of six independent experiments. (H) Knockdown of HDAC6
increases H2BK5 acetylation on the Galnt3 promoter in TSKI4H6sh cells relative to TSKI4
cells. H2BK5Ac ChIP-seq read density plots at the Galnt3 transcription start site + 20 kb
are shown. Red rectangle indicates region amplified in ChIP PCR reactions in panels (F)
and (G). Data are expressed as the normalized read count of the IP divided by the
normalized read count of the TSWT cell input. ** p-value < 0.01; *** p-value < 0.001,
Student’s t test. See also Figure S1.
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Knockdown of GALNT3 in TSWT cells induces EMT
To define the role of GALNT3 in TS cell EMT, we infected TSWT cells with
lentiviruses expressing two independent Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2 cells).
GALNT3 expression was reduced > 98% at both message and protein levels in TSWTGsh1
and TSWTGsh2 cells relative to TSWT cells (Figures 6A and 6B). Loss of GALNT3
expression in TSWTGsh1 and TSWTGsh2 cells induced a mesenchymal morphology similar to
TSKI4 cells (Figure 6C). Transcripts of epithelial genes Cdh1, Krt8, Krt18 and Cldn6 were
reduced in TSWTGsh1 and TSWTGsh2 cells relative to TSWT cells (Figure 6D). E-cadherin and
Claudin-6 protein levels were also diminished with GALNT3 knockdown (Figures 6E
and 6F). In addition to the loss of epithelial markers, TSWTGsh1 and TSWTGsh2 cells gained
the expression of mesenchymal markers Cdh2 and Vim and the EMT-inducing
transcription factors Twist1, Zeb1, and Snai2 (Figures 6G and 6H). Consistent with
changes in Claudin-6 transcript and protein, immunofluorescence confocal microscopy
showed reduced Claudin-6 expression and loss of co-localization with ZO1 at cell-cell
junctions in TSKI4 cells and TSWTGsh cells (Figure S2A). Further, fluorescent dye
exclusion assays showed increased permeability in TSKI4 cells and TSWTGsh cells relative
to TSWT cells (Figure 6I). These data suggested that loss of GALNT3 reduces epithelial
features and disrupts barrier formation.
A key feature of EMT is the acquisition of cell motility and/or invasiveness. Cell
movement assessed through live cell imaging showed TSWT cells remaining in a static
position while rapidly dividing (data not shown). In contrast, TSKI4 cells showed
frequent, rapid movements throughout the field (data not shown). Knockdown of
GALNT3 in TSWT cells increased motility similar to TSKI4 cells (data not shown). In
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addition to examining motility, we measured invasiveness using growth factor reduced
Matrigel-coated transwell assays. TSKI4, TSWTGsh1 and TSWTGsh2 cells displayed increased
invasiveness relative to TSWT cells, suggesting that loss of GALNT3 increases
invasiveness (Figure 6J). Although loss of GALNT3 induced EMT, cells lacking
GALNT3 retained the expression of stemness markers and the ability to differentiate into
all trophoblast subtypes, suggesting that stemness features were maintained in the
absence of GALNT3 (Figures S2B-S2I). These data showed that TS cells lacking
GALNT3, either through loss of MAP3K4 activity in TSKI4 cells or with shRNA
knockdown of GALNT3 in TSWT cells, expressed both stemness and EMT features.
Together, these data suggested that loss of GALNT3 in TS cells induces EMT.
We also examined the role of GALNT3 in HMECs by transiently expressing two
independent Galnt3 shRNAs. We were unable to achieve stable reduction of GALNT3
expression in HMECs, suggesting that GALNT3 performs key functions. Transient
expression of Galnt3 shRNAs resulted in the partial reduction of Galnt3 transcripts and
morphological changes that were similar to TSKI4 cells (Figures S2J and S2K). Control
infected HMECs formed epithelial colonies whereas GALNT3 knockdown cells were
individual with front to back polarity and long cytoplasmic extensions (Figure S2K).
Although total E-cadherin protein levels were unchanged with knockdown of GALNT3
in HMECs, cell movement was altered (Figure S2L and data not shown). Control infected
HMECs moved as sheets of cells (data not shown). In contrast, HMECs with GALNT3
knockdown moved more as individual cells with front to back polarity that was similar to
SUM159 cells (data not shown). Together, these data suggested that GALNT3 is
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important for maintaining the epithelial state in both TS cells and HMECs as reduced
expression of GALNT3 induced EMT characteristics.
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Figure 6. Knockdown of GALNT3 in TSWT cells induces EMT. (A) Transcripts were
measured using qPCR in TSWT and TSKI4 cells expressing control shRNA (C) or TSWT
cells expressing two independent Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2). (B) Western
blots of whole cell lysates are representative of three independent experiments. (N.S.,
Non-Specific). (C) GALNT3 knockdown in TSWT cells induces a mesenchymal
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Figure 6 (Continued)
morphology. Representative phase microscopy images from three independent
experiments are shown. Black bar represents 100 µm. (D) GALNT3 knockdown in TSWT
cells reduces epithelial marker expression in TSWTGsh1 and TSWTGsh2 cells. (E, F) Western
blots are representative of three independent experiments. (G, H) Increased transcripts of
mesenchymal markers (G) and EMT-inducing transcription factors (H) with reduced
Galnt3 expression are shown. (I) Impaired barrier formation in TSWTGsh1 and TSWTGsh2
cells with reduced GALNT3 expression. Diffusion of fluorescent dye across a confluent
monolayer of cells is expressed as a fold-change in fluorescence relative to TSWT cells.
Data shown are the mean ± SEM of three independent experiments. (J) Loss of GALNT3
increases invasiveness in TSWTGsh1 and TSWTGsh2 cells through growth factor reduced
Matrigel coated transwells. Data show cells per 10X field and are the mean ± range of
two independent experiments performed in triplicate. (A, D, G, H) qPCR data normalized
to Actb are expressed as a fold-change relative to TSWT cells and are the mean ± SEM of
three independent experiments. * p-value < 0.05; *** p-value < 0.001, Student’s t test.
See also Figures S2.
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Loss of Galnt3 in the blastocyst TE results in premature EMT
To further define the role of GALNT3 in TS cells, we examined the impact of loss
of GALNT3 in pre-implantation blastocysts. Mid-stage E3.5 blastocysts were hatched
and infected with lentiviruses expressing either control shRNA or Galnt3 shRNA. This
approach has previously been shown to only infect the TE layer of these intact blastocysts
(Georgiades et al., 2007). Using semi-quantitative PCR, we validated that infected
blastocysts expressed transcripts for the puromycin resistance gene encoded by these
viruses (Figure 7A). shRNA knockdown of Galnt3 in the TE of intact blastocysts resulted
in premature attachment and outgrowth compared to control shRNA infections (Figures
7B and 7C). Attachment of blastocysts with Galnt3 knockdown occurred eight hours
earlier than either control shRNA infected or uninfected blastocysts, suggesting that loss
of Galnt3 leads to premature EMT (Figure 7B). Together, these data demonstrate the role
of Galnt3 in EMT of the TE, which is the origin of TS cells.
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Figure 7. Reduction of Galnt3 expression in the trophectoderm of E3.5 blastocysts results
in premature EMT. (A) Semi-quantitative PCR gel for transcript expression of the
puromycin resistance gene (pac) is shown for blastocysts that are uninfected or infected
with lentiviruses expressing shControl or shGalnt3 constructs. a and b represent two
independent blastocysts that were infected with either shControl or shGalnt3 lentiviruses.
PCR gel shown is representative of seven independent blastocyst experiments. (B) Galnt3
knockdown in blastocysts induced premature attachment and outgrowth compared to
control infected blastocysts. Phase images show the timeline of infection and treatment of
both shControl and shGalnt3 infected blastocysts. TS, Trophoblast Stem cells; FGF4,
Fibroblast Growth Factor 4. Black bar represents 50 µm. (C) Reduced Galnt3 expression
results in early attachment of blastocysts. Quantitation of experiments as performed in
(B). n, total number of blastocysts assessed for shControl or shGalnt3 infections.
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Re-expression of GALNT3 in mesenchymal-like TSKI4 cells restores the epithelial state
Using a lentiviral construct for human Galnt3, we re-expressed GALNT3 in TSKI4
cells (TSKI4Gab1 and TSKI4Gab2 cells). Galnt3 transcripts were increased in TSKI4Gab1 and
TSKI4Gab2 cells relative to TSKI4 cells as measured with primers detecting both human and
mouse Galnt3 (Figure 8A). Similarly, GALNT3 protein levels in TSKI4Gab1 and TSKI4Gab2
cells were also increased relative to TSKI4 cells (Figures 8B and 8C). Importantly, reexpression of GALNT3 in TSKI4Gab cells restored an epithelial morphology in TSKI4 cells
that was similar to TSWT cells (Figure 8D). In addition, transcripts of epithelial markers
Krt8, Krt18, and Cldn6 were also increased in TSKI4Gab1 and TSKI4Gab2 cells relative to
TSKI4 cells (Figure 8E). Further, E-cadherin and Claudin-6 proteins were expressed in
TSKI4Gab1 and TSKI4Gab2 cells at levels similar to TSWT cells (Figures 8F and 8G).
Fluorescent dye flux was reduced in TSKI4Gab cells relative to TSKI4 cells, suggesting
partial restoration of tight junctions and barrier function with re-expression of GALNT3
(Figure 8H). Together, these data suggested that GALNT3 re-expression in TSKI4 cells
restored epithelial features.
Re-expression of GALNT3 in TSKI4 cells reduced the expression of mesenchymal
markers and EMT-inducing transcription factors. Although Cdh2 expression remained
elevated, TSKI4Gab1 and TSKI4Gab2 cells showed reduced expression of the mesenchymal
marker Vim and EMT-inducing transcription factors Twist1, Zeb1, and Snai2 relative to
TSKI4 cells (Figures 8I and 8J). Importantly, TSKI4Gab cells had reduced cell motility as
measured by live cell imaging and GALNT3 re-expression reduced invasiveness to TSWT
cell levels (data not shown and Figure 8K). Altogether, these data suggested that re-
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expression of GALNT3 in TSKI4 cells induces MET, restoring the epithelial phenotype in
TS cells.
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Figure 8. GALNT3 re-expression in TSKI4 cells restores an epithelial phenotype. (A)
Increased Galnt3 transcripts in TSKI4 cells expressing human GALNT3. Transcripts were
measured using qPCR in TSWT and TSKI4 cells infected with a control lentiviral construct
(C) or TSKI4 cells infected with a lentiviral construct expressing human Galnt3 (TSKI4Gab1
and TSKI4Gab2). (B, C) Re-expression of GALNT3 in TSKI4Gab1 and TSKI4Gab2 cells was
measured by Western blotting. (B) Blots are representative of three independent
experiments. (C) Densitometry was used to quantify three independent experiments. (D)
GALNT3 re-expression restores an epithelial morphology. Representative phase
microscopy images from three independent experiments are shown. Black bar represents
100 µm. (E) Increased transcripts of epithelial markers with re-expression of GALNT3.
(F, G) Western blots are representative of three independent experiments. (H) GALNT3
re-expression promotes barrier formation. Diffusion is expressed as a fold-change in
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Figure 8 (Continued)
fluorescence relative to TSWT cells. Data shown are the mean ± SEM of three
independent experiments. (I, J) Re-expression of GALNT3 reduces mesenchymal
markers (I) and EMT-inducing transcription factors (J). (K) Re-expression of GALNT3
in TSKI4 cells reduces invasiveness through growth factor reduced Matrigel. Data show
cells per 10X field and are the mean ± range of two independent experiments performed
in triplicate. (A, E, I, J) qPCR data normalized to Actb are expressed as a fold-change
relative to TSWT cells and are the mean ± SEM of three independent experiments. * pvalue < 0.05; ** p-value < 0.01; *** p-value < 0.001, Student’s t test.
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Re-expression of GALNT3 in CL SUM159 cells fails to restore epithelial state
In contrast to TSKI4 cells, re-expression of GALNT3 in SUM159 cells to levels
greater than HMECs failed to alter cell morphology (Figures 9A-9C). Although GALNT3
colocalized with the Golgi marker Giantin, epithelial proteins like E-cadherin and
claudins were not expressed, and mesenchymal markers and EMT inducing transcription
factors remained elevated (Figure 9D and data not shown). These data suggested that
unlike TS cells, GALNT3 re-expression was insufficient to restore the epithelial state in
SUM159 cells.
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Figure 9. GALNT3 re-expressed in CL SUM159 breast cancer cells localizes to the
Golgi. (A) Galnt3 transcripts analyzed by qPCR in CL SUM159 breast cancer cells
infected with a control virus (C) or a lentiviral construct expressing FLAG-tagged human
Galnt3 (SUM159Gab). qPCR data normalized to Tbp are expressed as a fold-change
relative to control infected CL SUM159 breast cancer cells and are the mean ± SEM of
two independent experiments. ***p-value < 0.001, Student’s t test. (B) Western blots for
GALNT3 and a-tubulin are shown and are representative of three independent
experiments. (C) Re-expression of GALNT3 in SUM159 cells does not alter morphology.
Phase microscopy images are representative of two independent experiments. Black bar
represents 100 µm. (D) FLAG-GALNT3 localizes to the Golgi in SUM159Gab cells.
Images are representative of two independent experiments. DAPI (blue), FLAGGALNT3 (green), Giantin (Golgi) (red). White bar represents 50 µm.
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Discussion

Herein, we define a critical role of GALNT3 in epithelial TS cells derived from
the preimplantation blastocyst. Loss of GALNT3 in TS cells induces EMT. Importantly,
re-expression of GALNT3 in mesenchymal-like TSKI4 cells restores the epithelial state. In
addition, we identify a conserved role for GALNT3 in HMECs, where loss of GALNT3
is associated with the gain of the mesenchymal state. Further, loss of Galnt3 in the
blastocyst trophectoderm results in premature attachment and outgrowth. Our work
defines a key role for GALNT3 in promoting the epithelial state in TS cells and HMECs.
This study identifies the role of a specific O-GalNAc glycosyltransferase in TS cells of
the early blastocyst.
In many cancers, heterogeneity in protein structures due to aberrant glycosylation
results in loss of cell-cell adhesion and gain of invasiveness. Changes in protein
glycosylation occur in two ways: incomplete synthesis and neo-synthesis (Pinho and
Reis, 2015). Loss of expression of initiating glycosyltransferases results in truncated
glycans and disrupted protein structures. In contrast, synthesis of glycosyltransferases not
normally expressed can lead to new carbohydrate structures on proteins that may trigger a
tumorigenic response (Pinho and Reis, 2015). Thus, transcriptional changes in the
expression of glycosyltransferases are a key factor associated with different types of
cancers. We show GALNT3 expression is nearly absent in CL SUM159 cells, and
knockdown of GALNT3 in HMECs results in phenotypic changes related to EMT.
Changes in GALNT3 expression have been implicated during cancer EMT. In poorly
differentiated pancreatic cancers, GALNT3 expression is reduced (Maupin et al., 2010).
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These same mesenchymal-like pancreatic cancers have loss of E-cadherin. Further,
knockdown of GALNT3 in differentiated pancreatic cancers induces EMT (Chugh et al.,
2016). In contrast, GALNT3 expression is increased in ovarian cancers including A2780s
cells (Wang et al., 2014). shRNA knockdown of GALNT3 in A2780s cells reduced
proliferation and invasiveness and increased E-cadherin. The authors suggested that these
effects were related to GALNT3-dependent MUC1 glycosylation (Wang et al., 2014).
Importantly, CL SUM159 cells that lack GALNT3 have a >90% decrease in MUC1
expression relative to HMECs, suggesting MUC1 glycosylation does not promote EMT
in CL SUM159 cells (Raghu, unpublished data). Differences in the impact of altered
GALNT3 expression may be due to the functions of GALNT3 in normal versus
cancerous tissues, and different stages and grades of cancer. Further, the absence or
presence of GALNT3 targets like MUC1 or differential activation of pathways triggering
GALNT3 mislocalization might lead to different responses in specific cancers (Chia et
al., 2016). Compensatory changes in the expression of other GALNTs may also result in
different outcomes. Wang et al. showed that Galnt14 expression was strongly reduced
with GALNT3 knockdown in A2780s. Our data emphasize a key role for GALNT3 in the
maintenance of the epithelial state in TS cells, but its role in cancer cells may be
dependent on cell type-specific expression of GALNT3 and its targets.
A key feature of EMT is the loss of tight junction proteins. shRNA knockdown of
GALNT3 completely disrupts tight junction assembly. Importantly, re-expression of
GALNT3 in the TSKI4 cells restores tight junction protein expression and barrier function.
We have previously shown that HDAC6 directly deacetylates H2BK5 on the promoter of
a key tight junction protein, Cldn6, repressing its expression (Mobley et al., 2017).
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Similar to Cldn6, we show that HDAC6 represses Galnt3 expression by directly
deacetylating H2BK5 on the Galnt3 promoter. These data suggest that HDAC6 controls
the expression of several key genes that promote the epithelial state and repression of
these genes results in EMT. Importantly, in TSKI4 cells that have elevated HDAC6 levels,
re-expression of GALNT3 restores the expression and localization of Claudin-6. These
data suggest that GALNT3 may regulate other key targets that control the expression and
localization of Claudin-6. Together, these data demonstrate that the
MAP3K4/HDAC6/H2BK5Ac co-regulated gene, Galnt3, plays a key role in regulating
tight junction assembly.
In summary, we define a post-translational mechanism of EMT regulation
through GALNT3 in TS cells and HMECs. Loss of GALNT3 in the TS cells, blastocyst
trophectoderm, and HMECs induces EMT. We predict that GALNT3 promotes the OGalNAc glycosylation of key targets that are important in regulating EMT in TS cells,
and future work will focus on identifying these targets. In addition, we observe that loss
of GALNT3 results in EMT in the preimplantation blastocysts, suggesting a possible role
for GALNT3 during early development. Together, our work provides insights into
GALNT3 mediated EMT events occurring during developmental EMT that may be
reactivated during cancer progression.
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Supplemental Figures

Figure S1. HDAC6 epigenetically inhibits the promoters of epithelial genes in SUM159
Claudin-low breast cancer cells. Related to Figure 5. (A) Increased nuclear HDAC6 in
SUM159 Claudin-low (CL) breast cancer cells relative to HMECs. Western blots are
representative of three independent experiments. (B) Anti-HDAC6 ChIP-PCR shows the
efficiency of anti-HDAC6 antibody versus Immunoglobulin G (IgG) control in TSKI4
cells. Data shown are the mean ± SEM of two independent experiments. (C) AntiH2BK5Ac ChIP-PCR shows the efficiency of anti-H2BK5Ac antibody versus IgG
control in TSWT cells. Data shown are the mean ± SEM of two independent experiments.
(D) Immunoprecipitation (IP) efficiency of the anti-HDAC6 antibody relative to IgG
control in HMECs as shown by Western blotting. Blots are representative of two
independent experiments. (E) Anti-HDAC6 ChIP-PCR shows increased HDAC6
enrichment on the promoters of specific genes in SUM159 CL breast cancer cells relative
to HMECs. Data shown are the mean ± SEM of three independent experiments. (F)
Decreased H2BK5 acetylation on the promoters of specific genes in SUM159 CL breast
cancer cells relative to HMECs as measured by anti-H2BK5Ac ChIP-PCR. HMEC
chromatin was immunoprecipitated with either IgG or anti-H2BK5Ac antibody. Data
shown are the mean ± SEM of three independent experiments. *p-value < 0.05, ***pvalue < 0.001, not significant (n.s.), Student’s t test.
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Figure S2. TS cells lacking GALNT3 maintain the expression of stemness markers and
the ability to differentiate into all trophoblast subtypes. Related to Figure 6. (A) Reduced
Claudin-6 and ZO1 protein expression and localization in cells lacking GALNT3.
Confocal images in TSWT and TSKI4 cells expressing control shRNA or TSWT cells
expressing two independent Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2) are shown. Images
are representative of three independent experiments. DAPI (blue), Claudin-6 (green),
ZO1 (red). White bar represents 50 µm. (B-E) Undifferentiated TSWTGsh1 and TSWTGsh2
cells maintain stemness marker expression as measured by qPCR. Differentiation was
induced by FGF4 withdrawal for the indicated number of days. (F-I) Differentiation of
TSWTGsh1 and TSWTGsh2 cells induces the expression of trophoblast differentiation markers
suggesting the maintenance of multipotency. Experiments were performed as in (B-E).
(J) shRNA knockdown of Galnt3 in HMECs. Transcript levels were measured using
qPCR in HMECs expressing a control shRNA (C) or two independent Galnt3 shRNAs
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Figure S2 (Continued)
(Gsh1 and Gsh2) and SUM159 cells. qPCR data normalized to Gapdh are expressed as a
fold-change relative to HMECs and are the mean ± SEM of three independent
experiments. *** p-value < 0.001, Student’s t test. (K) shRNA knockdown of GALNT3
in HMECs induces a mesenchymal morphology. Phase microscopy images of HMEC,
HMECGsh1 and HMECGsh2 cells are shown. Images are representative of three
independent experiments. Arrowheads show cytoplasmic, mesenchymal-like extensions
that are induced with Galnt3 knockdown in epithelial HMECs. Black bar represents 100
µm. (L) E-cadherin protein levels are unchanged with loss of GALNT3 in HMECs.
Western blots are representative of three independent experiments. (B-I) qPCR data
normalized to Actb are expressed as a fold-change relative to undifferentiated TSWT cells
(0 day) and are the mean ± range of two independent experiments.
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Chapter III
GALNT3 Mediated O-GalNAc Glycosylation of E-cadherin Promotes the Epithelial
State in Trophoblast Stem Cells and Human Mammary Epithelial Cells
Introduction
Epithelial to mesenchymal transition (EMT) is a reversible morphogenetic
program, where the non-motile epithelial cells convert to motile mesenchymal cells.
EMT is a critical developmental process important for tissue regeneration and wound
healing (Thiery et al., 2009; Yang and Weinberg, 2008). Importantly, EMT is reactivated
during cancer metastasis (Chapman, 2011; De Craene and Berx, 2013). We have
previously shown that a MAP3K4/HDAC6/H2BK5Ac dependent gene, GALNT3,
regulates EMT and controls the cellular phenotype in both TS cells and mammary cells
(Chapter II). Lentiviral shRNA knockdown of Galnt3 in the TSWT cells and HMECs
induces EMT (Chapter II). For the first time, we have shown the impact of GALNT3 on
EMT in the blastocyst TE (Chapter II). Loss of Galnt3 in the preimplantation blastocyst
TE results in premature EMT. Together, these data suggest that GALNT3 is a key
regulator of EMT in TS cells and HMECs.
The preimplantation blastocyst TE is the origin of TS cells. The TS cells isolated
from wild-type mice display an epithelial morphology with tight cell-cell adhesion (Abell
et al., 2011). In contrast, TS cells isolated from Kinase-Inactive MAP3K4 (KI4) mice
display a mesenchymal morphology with reduced cell-cell adhesion (Abell et al., 2011).
Further, KI4 embryos display severe developmental defects that are caused by
perturbations in the process of EMT (Abell et al., 2009; Abell and Johnson, 2005). TSKI4
cells that have undergone EMT retain features of stemness including self-renewal and
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multipotency (Abell et al., 2011). We have previously shown that the mesenchymal TSKI4
cells have a 70% decrease in the expression of GALNT3 relative to TSWT cells (Chapter
II). Importantly, Galnt3 expression is significantly reduced in all the Claudin-low (CL)
breast cancer cells relative to HMECs (Chapter II). These data indicate that GALNT3 is
critical for epithelial state maintenance.
The Galnt3 gene encodes for UDP-GalNAc Transferase 3. GALNT3 initiates the
attachment of N-acetylgalactosamine (GalNAc) to hydroxyl groups of serine or threonine
residues on specific proteins in the Golgi (Bennett et al., 2012). The function of GALNT3
is to promote folding and localization of membrane and secreted proteins. Mutations in
GALNT3 result in the misfolding of a phosphate homeostasis hormone, FGF23, the only
known target of GALNT3. Aberrant folding of FGF23 causes a severe autosomal
disorder called Hyperphosphatemic Familial Tumoral Calcinosis (Topaz et al., 2004). We
have shown that GALNT3 is a key regulator of EMT during development in the TS cells
(Chapter II). However, the protein targets glycosylated by GALNT3 are unknown.
In Chapter II, we showed that GALNT3 is important in the maintenance of the
epithelial state. Loss of GALNT3 expression in TS cells, blastocyst TE, and HMECs
resulted in the acquisition of the mesenchymal state. Importantly, GALNT3 re-expression
in the mesenchymal TSKI4 cells restored the epithelial phenotype. Herein, we identify
proteins with GALNT3 dependent O-GalNAc glycosylation and defined a mechanism by
which GALNT3 controls the cellular phenotype. Our findings show that changes in
GALNT3 expression alters the total O-GalNAc levels in both TS cells and HMECs.
Importantly, in TSWT cells, GALNT3 promotes initiation of O-GalNAc on multiple
proteins including E-cadherin resulting in the cell surface localization of E-cadherin,
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linear adherens junction (AJ) assembly, and epithelial state maintenance. Loss of
GALNT3 expression in TSKI4 cells reduces O-GalNAc glycosylation of E-cadherin and
increases the intracellular retention of E-cadherin in the Golgi. GALNT3 re-expression in
TSKI4 cells restores E-cadherin localization to the plasma membrane and leads to an
epithelial state. Together, our findings demonstrate that GALNT3 protects the epithelial
phenotype in TS cells and HMECs, by promoting O-GalNAc glycosylation of proteins
including E-cadherin.
Materials and Methods
Animals
See Chapter II Materials and Methods.
Cell lines and culture conditions
See Chapter II Materials and Methods.
Plasmids
See Chapter II Materials and Methods. To create an E-cadherin lentiviral
construct, we used pENTR-Cdh1 plasmid # 49776 Gateway entry vector. The insert was
cloned into a lentiviral FLAG tagged destination vector (Jordan et al., 2013) using LR
clonase II enzyme mix (Invitrogen). pENTR-Cdh1 was a gift from Jamie Davies
(Addgene plasmid#49776; http://n2t.net/addgene:49776; RRID:Addgene_49776).
Site directed mutagenesis
Q5 Site-Directed Mutagenesis Kit (NEB) was used to create single substitutions
in pENTR-Cdh1 at threonine at positions 40, 63 and 68 to alanine. Briefly, PCR
amplification was performed with custom designed mutagenesis primers for substitutions
created using NEBaseChanger software (NEB). The PCR amplified product was treated
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with Kinase-Ligase-DpnI (KLD) enzyme mix for 5 min to degrade the parent templates.
The KLD product was transformed into high-efficiency NEB 5-alpha competent E.coli.
The transformed bacteria were grown for 16 hours and plasmids were purified using
GeneJet miniprep kit (Thermo Fisher Scientific). The plasmids were validated for
substitution mutations through Sanger sequencing at the Molecular Resource Center at
the University of Tennessee Health Science Center. The custom designed primers are
listed in the Appendix E.
Lentiviral production and infection
See Chapter II Materials and Methods.
Real-time quantitative PCR
See Chapter II Materials and Methods.
Immunoprecipitation
For E-cadherin immunoprecipitations, cells lysed in buffer A plus protease and
phosphatase inhibitors as described in Chapter II were incubated for 1 hour with anti-Ecadherin antibody (Abcam). Then, lysates were incubated for 2 hours with Protein A
sepharose beads (Invitrogen) and then centrifuged at 1000 rpm for 1 min at RT.
Immunoprecipitates were washed four times with buffer A + PMSF and then boiled in
2X Laemli buffer for 7 min. Immunoprecipitates were separated by SDS-PAGE and
proteins were transferred onto nitrocellulose overnight. Next day, membranes were
washed in distilled water for 15 min and blocked with 1X carbo-free block (Vector
Laboratories) for 30 min at room temperature. Biotinylated VVL (5 µg/ml) was used to
probe membranes for 30 min at room temperature. Phosphate buffered saline (1X) with
0.5% Tween was used to wash membranes for 30 min. Membranes were probed with
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streptavidin HRP (1:500) (Invitrogen) for 1 hour at room temperature in the dark. Clarity
ECL (Bio-Rad) treated membranes were imaged and quantified using a Bio-Rad
ChemiDoc and Image lab software respectively.
Vicia villosa lectin assays
For VVL pull down assays, cells lysed in buffer A plus protease and phosphatase
inhibitors were incubated for 2 hours with VVL agarose beads (Vector Laboratories) and
then centrifuged at 1000 rpm for 1 min at RT. Immunoprecipitates were washed four
times with buffer A + PMSF and then boiled in 2X Laemmli buffer for 7 min.
Immunoprecipitates were separated by 7.5% SDS-PAGE and proteins were transferred
onto nitrocellulose. Samples were then probed with the indicated antibodies detailed in
Appendix A. For E-cadherin immunoprecipitations, cells lysed in buffer A plus protease
and phosphatase inhibitors were incubated for 1 hour with anti-E-cadherin antibody
(Abcam). Then, lysates were incubated for 2 hours with Protein A sepharose beads
(Thermo Fisher Scientific). Immunoprecipitates were washed four times with buffer A +
PMSF and then boiled in 2X Laemmli buffer for 7 min. Immunoprecipitates were
separated by 7.5% SDS-PAGE and proteins were transferred onto nitrocellulose
overnight. Next day, membranes were washed in distilled water for 15 min and blocked
with 1X carbo-free block (Vector Laboratories) for 30 min at room temperature.
Biotinylated VVL (5 µg/ml) was used to probe membranes for 30 min at room
temperature. Phosphate buffered saline (1X) with 0.5% Tween was used to wash
membranes for 30 min. Membranes were probed with streptavidin HRP (1:500) (Thermo
Fisher Scientific) for 1 hour at room temperature in the dark. Clarity ECL (Bio-Rad)
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treated membranes were imaged and quantified using a Bio-Rad ChemiDoc and Image
lab software, respectively.
VVL immunostaining
For VVL immunofluorescence staining, TS cells were cultured on glass
coverslips for two days. For both intact and detergent permeabilized VVL staining, cells
were fixed with 3% paraformaldehyde in 1X PBS for 10 min and then washed three times
with 1X PBS. Coverslips for permeabilized VVL staining were treated with 0.1 % Triton
for 3 mins and then washed three times with 1X PBS. Intact and permeabilized VVL
coverslips were blocked with 1X carbo-free block (Vector laboratories) for 30 min at RT.
Then, coverslips were incubated with 5 µg/ml of biotinylated VVL (Vector Laboratories)
in 1X PBS for 30 min at RT. Next, cells were washed five times with 1X PBS-Tween
(0.1%) and then incubated with DAPI (0.1 µg/ml) and 1:500 of Streptavidin-Alexa 488
(Thermo Fisher Scientific) or Streptavidin-Alexa 594 for one hour at RT. Coverslips
were washed and mounted on slides with mounting media and imaged. For colocalization of Golgi and VVL, cells were first incubated with anti-Giantin antibody
(Abcam) overnight at 4C and the next day VVL staining was performed.
Immunofluorescence imaging
Immunofluorescence imaging was performed using Nikon A1 laser scanning
confocal microscopy and a 60X Plan Apochromat 1.4 numerical-aperture (NA) oil
objective with lasers at 408, 488 and 594 nm. Individual Z-stacks and the 2D images
were obtained by either Maximum Intensity Projection (MIP) or Extended Depth of Field
(EDF) for all wavelengths. Confocal images for E-cadherin/Giantin were obtained using
MIP. Confocal images for Claudin6/ZO1, E-cadherin, E-cadherin/d-catenin, and
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Actin/Vinculin were obtained using EDF. Confocal 3D images shown were obtained
using NIS elements analysis software. Images displayed are a reconstruction of all the zstacks with a step size of 0.413 µm. The pixel resolution of each section is 512 X 512.
Imaging of in vitro biotinylated VVL staining experiments were performed using EVOS
epifluorescence microscope at 20X and 40X magnification for 408, 488 and 594 nm
wavelengths.
Blastocyst immunostaining
Wild-type 129/SvEv mice were euthanized 3.5 days post-mating. The uterus was
isolated and washed in KSOM-Hepes buffer (Millipore Sigma). The utero-tubule
junctions were cut and the uterine horns were flushed using a 25 gauge needle filled with
0.4 ml of M2 medium (Millipore Sigma). Using a mouth-controlled Pasteur pipette,
blastocysts were collected and transferred into a drop of PBS. Blastocysts were hatched
by serial passage through drops of Acid Tyrodes (Millipore Sigma). Hatched blastocysts
were transferred into drops of PBS, and then fixed in 3% paraformaldehyde and VVL
immunofluorescence staining was performed as described under Vicia villosa lectin
assays. Blastocyst images were obtained using EVOS epifluorescence and Nikon A1
laser scanning confocal microscopes. Immunostaining of the trophectoderm of intact,
infected blastocysts was performed 48 hours post-infection. The shControl or shGalnt3
infected blastocysts were fixed with 3% paraformaldehyde and blocked for 30 min using
1X carbofree block. Blastocysts were stained for 1 hour using VVL-FITC (Vector
Laboratories) at room temperature. The VVL-FITC stained blastocysts were imaged at
20X using EVOS microscopy.
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VVL staining quantitation
TS cells were plated for two days and cells were lifted using enzyme free PBS
based cell dissociation solution (Millipore Sigma). Cells were centrifuged at 1000 rpm
for 3 min and cell pellets were washed in 1X PBS. For both intact and detergent
permeabilized cells, VVL staining was performed as described under
Immunofluorescence Staining and all procedures were performed on ice. The stained
cells were resuspended in 400 µl 2% FBS in 1X PBS and 100 µl of the resuspended cells
were plated in a 96 well plate. Immunofluorescence staining for cell surface and
permeabilized VVL (green) was measured using a LionHeart FX automated live cell
imager (BioTek). For quantitation, beacons were set for each cell type using BioTek
Gen5 (version 3.02) software. The LionHeart FX captured 3 X 3 20X montages for DAPI
(Blue) and VVL (Green) for each cell type. Using BioTek Gen5 (version 3.02) software,
montages were stitched together, and cellular analysis was performed. Parameters used
for quantitation included total cell count, integrated green intensity (Total VVL intensity)
and percentage of cells positive for green (VVL). Data were plotted using GraphPad
Prism7.
Statistical methods
See Chapter II Materials and Methods.
For qPCR data, the Bio-Rad CFX Maestro software (version 3.0) was used to
perform a Student’s t test corrected for multiple comparisons. For all other statistics
shown, Prism7 (version 7.0, GraphPad software) was used to perform a Student’s t test
corrected for multiple comparisons or ANOVA with Bonferroni’s Multiple Comparison
test was used to analyze VVL quantitation.
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NIS-Elements
For blastocyst VVL-FITC quantitation, NIS analysis elements software was used
to measure the intensity of VVL-FITC (green) in the trophectoderm. To measure the
intensity of VVL, the Region of Interest Tool was used to select the trophectoderm area
and the Perform Measurements Tool was used to determine the intensity. The VVL-FITC
intensity for the blastocysts was analyzed and plotted using GraphPad Prism7 (version
7.0).
Results
Decreased O-GalNAc glycosylation with loss of GALNT3
GALNT3 is an O-GalNAc glycosyltransferase localized to the Golgi that modifies
specific S/T with the sugar residue GalNAc. In most cell types, O-GalNAc is further
modified by additional enzymes that extend the sugar, adding galactose, GlcNAc and/or
sialic acid (Bennett et al., 2012). Vicia Villosa Lectin (VVL) binds with high affinity to
unmodified O-GalNAc residues. Using this lectin, we measured the amount of
unextended O-GalNAc labeled proteins in TSWT cells relative to TSKI4 cells. Whole cell
lysates were immunoprecipitated with agarose bound VVL, and blots were probed with
biotinylated VVL. Unmodified O-GalNAc labeled proteins were detected in TSWT cells at
higher levels relative to TSKI4 cells that have reduced GALNT3 expression (Figure 10A).
Further, shRNA knockdown of Galnt3 in TSWT cells resulted in the near complete loss of
O-GalNAc labeled proteins (Figure 10A). Importantly, re-expression of GALNT3 in
TSKI4 cells and in SUM159 cells increased the levels of O-GalNAc labeled proteins
(Figure 10B and Figure S3A). Knockdown of HDAC6 in TSKI4 cells also increased OGalNAc to levels similar to TSWT cells (Figure 10C). VVL binding was also reduced in
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HMECs expressing Galnt3 shRNAs and in CL SUM159 cells relative to HMECs
(Figures S3B and S3C). These data suggested that EMT in TS cells and HMECs was
associated with loss of O-GalNAc labeled proteins.
We also used biotinylated VVL and immunofluorescence to examine the
localization of O-GalNAc labeled proteins in intact or detergent permeabilized cells.
Surprisingly, TSWT cells showed strong cell surface expression of VVL labeled proteins
in non-permeabilized cells that was weaker in TSKI4 cells or undetectable in TSWTGsh cells
lacking GALNT3 (Figure 10D and Figures S3D). TSKI4Gab cells showed increased cell
surface VVL staining relative to TSKI4 cells (Figure 10D). Quantitation revealed that
>90% of TSWT cells were positive for cell surface VVL staining, compared to 45% of
TSKI4 cells, and 0.5% TSWTGsh cells (Figure S3E). Similar to cultured TS cells, the TE
layer of intact wild-type blastocysts displayed significant VVL staining, suggesting the
presence of unextended O-GalNAc modified proteins (Figure 10E and S3F). Detergentpermeabilization revealed intracellular VVL staining that was tightly localized to puncta
positioned near the nucleus in all cell conditions (Figure S3G). However, total VVL
staining intensity in permeabilized cells was reduced in TSKI4 cells and nearly absent in
TSWTGsh cells, consistent with Western blotting data (Figures 10A, 10D and Figures S3DS3G). Co-localization of VVL and the Golgi marker Giantin was greater in TSKI4 cells
relative to TSWT cells (Figure 10F). Together, these data suggested that loss of GALNT3
reduced O-GalNAc labeled proteins at the cell surface.
The presence of low levels of O-GalNAc labeled proteins in TSKI4 cells and
TSWTGsh cells suggested that other GALNTs may be alternatively expressed after loss of
GALNT3. TSKI4 cells showed a modest increase in several of the GALNTs relative to
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TSWT cells that was reduced by re-expression of GALNT3 in TSKI4Gab cells (Figure S3H).
Importantly, knockdown of GALNT3 in TSWTGsh cells did not induce transcripts of other
GALNTs except Galnt7 and Galnt12 (Figure S3I). Together, these data suggested that
GALNT3 is the dominant O-GalNAc glycosyltransferase in TS cells.

74

Figure 10. Reduced O-GalNAc glycosylation in cells lacking GALNT3 that is restored by
re-expression of GALNT3. (A) Total protein O-GalNAc glycosylation is reduced with
loss of GALNT3 in TSWTGsh1 and TSWTGsh2 cells. IP with VVL-agarose and blotting with
biotinylated VVL is shown. Western blots of TSWT and TSKI4 cells expressing control
shRNA (C) or TSWT cells expressing two independent Galnt3 shRNAs (TSWTGsh1 and
TSWTGsh2) are representative of three independent experiments. (B) Re-expression of
GALNT3 in TSKI4 cells (TSKI4Gab1 and TSKI4Gab2) increases protein O-GalNAc
glycosylation. Experiments were performed as in (A). Western blots of TSWT and TSKI4
cells expressing a control lentiviral vector (C) or or TSKI4 cells infected with a lentiviral
vector expressing human Galnt3 (TSKI4Gab1 and TSKI4Gab2) are representative of three
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Figure 10 (Continued)
independent experiments. (C) Knockdown of HDAC6 in TSKI4 cells (TSKI4H6sh) increases
total protein O-GalNAc glycosylation similar to TSWT cells. Experiments were performed
as in (A). Western blots of TSWT cells and TSKI4 cells expressing control shRNA (C) or
TSKI4 cells expressing HDAC6 shRNA (TSKI4H6sh) are representative of two independent
experiments. (D) Absence of cell surface O-GalNAc glycosylation in TSKI4 and TSWTGsh
cells with reduced GALNT3. VVL immunofluorescence staining in non-permeabilized
TSWT and TSKI4 cells infected with a control virus, TSWT cells infected with Galnt3
shRNA (TSWTGsh), and TSKI4 cells re-expressing GALNT3 (TSKI4Gab) are shown. Images
are representative of three independent experiments. (E) O-GalNAc glycosylation of the
trophoectoderm (TE) of intact wild-type E3.5 hatched blastocyst is shown by confocal
microscopy using biotinylated VVL. Image is representative of seven blastocysts. DAPI
(blue), VVL (green). (F) Reduced GALNT3 expression in TSKI4 cells induces retention of
O-GalNAc glycosylated proteins in the Golgi. DAPI (blue), VVL (red) and Giantin
(Golgi) (green) staining of Triton permeabilized cells. Arrowheads show co-localization
between VVL and Giantin in the Golgi. Images are representative of three independent
experiments. IP, Immunoprecipitation; MW, Molecular weight in kDa; White bar
represents 50 µm. See also Figure S3.
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Loss of Galnt3 in the blastocyst TE results in reduced O-GalNAc staining
To further define the role of GALNT3 mediated O-GalNAc glycosylation in TS
cells, we examined the impact of loss of GALNT3 in pre-implantation blastocyst TE. The
cell surface VVL staining of the TE was reduced by 57% in blastocysts infected with
Galnt3 shRNAs compared to control shRNA infections (Figures 11A and 11B). These
data suggest that loss of Galnt3 at the blastocyst TE reduces O-GalNAc glycosylation
staining. Examination of VVL staining of uninfected blastocysts during attachment and
outgrowth revealed the reduction of VVL staining with attachment and outgrowth (Figure
11C). Together, these data suggest that the loss of cell surface O-GalNAc labeled
proteins on the TE may represent a normal process during blastocyst development.
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Figure 11. Knockdown of Galnt3 in the trophectoderm of E3.5 blastocysts results in
reduced O-GalNAc glycosylation staining. (A) Decreased O-GalNAc staining intensity
on the trophectoderm of shGalnt3 blastocysts relative to control infected blastocysts.
Epifluorescence images shown are representative of seven independent experiments.
DAPI (blue), VVL-FITC (green). Arrows indicate area of enlarged insets. Arrowheads
indicate VVL-FITC staining. White bar represents 50 µm. (B) Quantification of VVLFITC intensity on the trophectoderm of shControl and shGalnt3 infected blastocysts is
shown. Data are expressed as a fold change relative to control infected blastocysts and
are the mean ± SEM of seven infected blastocysts. ****p-value < 0.0001, Student’s t test.
(C) Differentiation and outgrowth of the trophectoderm results in decreased O-GalNAc
staining. Arrow indicates the area of trophoblast outgrowth initiation that is associated
with decreased O-GalNAc staining. Arrowheads indicate the area for differentiated
trophoblast cells correlated with loss of O-GalNAc staining. DAPI (blue), VVL-FITC
(green). White bar represents 50 µm.
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E-cadherin O-GalNAc glycosylation is dependent on GALNT3
Loss of GALNT3 reduced total levels of O-GalNAc glycosylated proteins in TS
cells, suggesting that GALNT3 promotes the O-GalNAc glycosylation of multiple
proteins in TS cells (Figures 10A-10C). Examination of VVL blots revealed reduced OGalNAc glycosylation of a protein of ~140 kDa in TSKI4 and TSWTGsh cells that is
restored in TSKI4Gab cells and TSKI4H6sh cells (Figures 10A-10C). Although the calculated
mass of E-cadherin is 97.5 kDa, E-cadherin migrates around 135 kDa on polyacrylamide
gels. In addition, E-cadherin was recently shown by mass spectrometry to be modified
with a single O-GalNAc on the first extracellular cadherin domain (EC1) at threonine
position 63, but the function of this modification and the O-GalNAc glycosyltransferases
were undefined (Vester-Christensen et al., 2013). Further, our previously published work
shows that E-cadherin is intracellularly retained in TSKI4 cells (Mobley et al., 2017).
Based on the changes in O-GalNAc levels at ~140 kDa and altered localization of Ecadherin, we predicted that GALNT3 may be required for O-GalNAc glycosylation of Ecadherin. Immunoprecipitation of lysates with VVL-agarose and probing with anti-Ecadherin antibody revealed O-GalNAc labeled E-cadherin in TSWT cells that was lost in
TSKI4 cells and in TSWTGsh cells (Figure 12A). Immunoprecipitation with anti-E-cadherin
antibody and probing with VVL-biotin also showed O-GalNAc glycosylation of Ecadherin in TSWT cells that was diminished in TSKI4 and TSWTGsh cells (Figure 12B). A
similar loss of O-GalNAc labeled E-cadherin was observed with knockdown of GALNT3
in HMECs and in SUM159 cells relative to HMECs (Figures 12C and 12D). Knockdown
of HDAC6 in TSKI4 cells to levels that restore GALNT3 expression and GALNT3 reexpression in TSKI4Gab cells increased O-GalNAc modification of E-cadherin (Figures
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12A-B and Figure 12E). These data suggest that E-cadherin is O-GalNAc modified in a
GALNT3 dependent manner. Based on the previous work from Vester-Christensen et al.
using mass spectrometry, we predicted that threonine at position 63 on E-cadherin is OGalNAc glycosylated in a GALNT3 dependent manner. We mutated threonine at
positions 40, 63, and 68 in the E-cadherin EC1 domain to alanine. These mutated proteins
were expressed in CL SUM159 cells stably transduced with GALNT3. Substitutions of
threonine 63 to alanine in E-cadherin resulted in a 50% decrease in O-GalNAc
glycosylation of E-cadherin relative to wild-type E-cadherin (Figures 12F and 12G).
Together, these data suggest that GALNT3 promotes O-GalNAc glycosylation of Ecadherin in both TS cells and HMECs.
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Figure 12. Reduced O-GalNAc glycosylation of E-cadherin in cells lacking GALNT3
that is restored by re-expression of GALNT3. (A) O-GalNAc glycosylation of E-cadherin
is reduced in cells lacking GALNT3. IP with VVL-agarose and blotting with anti-Ecadherin antibody is shown for the indicated cells. Western blots are representative of
three independent experiments. (B) Cells lacking GALNT3 show reduced O-GalNAc
glycosylation of E-cadherin. IP with Immunoglobulin G (IgG) antibody or anti-Ecadherin antibody and blotting with VVL biotin is shown for TSWT and TSKI4 cells
infected with a control virus, TSWT cells infected with Galnt3 shRNA (TSWTGsh), and
TSKI4 cells re-expressing Galnt3 (TSKI4Gab). Western blots are representative of three
independent experiments. (C) O-GalNAc glycosylation of E-cadherin is reduced in
HMECs lacking GALNT3. IP with VVL-agarose and blotting with anti-E-cadherin
antibody is shown for the indicated cells. Western blots are representative of three
independent experiments. (D) CL SUM159 cells lacking GALNT3 have reduced OGalNAc glycosylation of E-cadherin. IP with VVL agarose beads and blotting with antiE-cadherin antibody is shown for the indicated cells. Western blots are representative of
three independent experiments. (E) Knockdown of HDAC6 increases E-cadherin OGalNAc glycosylation in TSKI4H6sh cells. Experiments were performed as in (A). Western
blots are representative of two independent experiments. (F, G) Reduced GALNT3
dependent O-GalNAc glycosylation of E-cadherin with the substitution of threonine at
position 63 to alanine. Control (C) SUM159 cells or SUM159 cells expressing FLAG
tagged human Galnt3 (SUM159Gab) were infected with wild-type (WT) E-cadherin or
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Figure 12 (Continued)
E-cadherin with substitution mutations in threonine at positions 40, 63, or 68 to alanine
(T40A, T63A and T68A) are shown. IP with VVL-agarose and blotting with E-cadherin,
and total E-cadherin blots are shown. Blots are representative of three independent
experiments. (G) Bar graph shows the densitometry analyses of Western Blots from three
independent experiments. O-GalNAc glycosylation of E-cadherin levels were normalized
to total E-cadherin. Data are expressed as a fold change relative to WT E-cadherin
infected SUM159Gab and show the mean ± SEM of three independent experiments. ***pvalue < 0.001, not significant (n.s.), Student’s t test. IP, Immunoprecipitation
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GALNT3 controls the localization of E-cadherin
E-cadherin expression at both transcript and protein levels was similar in TSWT
and TSKI4 cells (Figures 6E and 6F). However, confocal immunofluorescence microscopy
showed a change in E-cadherin localization from the plasma membrane in TSWT cells to
the Golgi in TSKI4 cells as indicated by a 54% increase in co-localization of E-cadherin
with a Golgi marker, Giantin (Figure 13A). Importantly, cell surface E-cadherin
localization was restored in TSKI4Gab cells, suggesting that GALNT3 controls E-cadherin
localization (Figure 13A). Similarly, knockdown of HDAC6, a deacetylase that normally
represses Galnt3 expression, restores E-cadherin localization to the plasma membrane
(Figure 13B). Knockdown of GALNT3 in HMECs resulted in E-cadherin retention in the
Golgi (Figure 13C and data not shown). Together these data suggested that loss of
GALNT3 in TSKI4 cells and HMECs with GALNT3 knockdown results in the
intracellular retention of E-cadherin in the Golgi. Re-expression of GALNT3 in TSKI4
cells through either HDAC6 knockdown or a GALNT3 lentiviral construct restored the
localization of E-cadherin to the plasma membrane.
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Figure 13. Loss of GALNT3 results in the intracellular retention of E-cadherin in the
Golgi. (A) Reduced GALNT3 expression in TSKI4 cells results in the retention of Ecadherin in the Golgi. Confocal images in TSWT and TSKI4 cells infected with a control
virus, TSWT cells infected with Galnt3 shRNA (TSWTGsh) and TSKI4 cells expressing
human GALNT3 (TSKI4Gab) are shown. DAPI (blue), E-cadherin (green) and Giantin
(Golgi) (red). Arrowheads indicate co-localization of E-cadherin and Giantin in the
Golgi. (B) HDAC6 knockdown in TSKI4 cells results in the partial restoration of Ecadherin to the cell surface. Confocal images in TSWT cells and TSKI4 cells expressing
control shRNA or TSKI4 cells expressing Hdac6 shRNA (TSKI4H6sh) are shown. Arrows
show the area of enlarged insets. Arrowheads indicate punctate intracellular E-cadherin
localization. (C) GALNT3 knockdown in HMECs results in the intracellular trapping of
E-cadherin. Confocal images for HMECs infected with a control shRNA or two
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Figure 13 (Continued)
independent Galnt3 shRNAs (HMECGsh1 and HMECGsh2) are shown. (A-C) Images are
representative of three independent experiments. White bar represents 50 µm.
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Loss of GALNT3 disrupts the assembly of adherens junctions
Loss of E-cadherin often leads to disruption of AJ assembly (Gumbiner, 1996).
TSKI4, TSKI4Gab, and TSKI4H6sh cells expressed a-catenin and d-catenin protein at levels
similar to TSWT cells (Figures 14A and 14B). In addition, transient knockdown of
GALNT3 in HMECs resulted in modest changes in a-catenin and d-catenin protein levels
relative to control infected HMECs (Figure 14C). Although total protein expression was
unchanged in TSKI4 cells, localization of AJ proteins was altered (Figure 14D). Unlike
TSWT cells with AJ components E-cadherin, a-catenin, and d-catenin co-localizing at
cell-cell junctions, cell surface expression of all AJ components was reduced in TSKI4
cells, resulting in loss of co-localization (Figure 14D and data not shown). Re-expression
of GALNT3 in TSKI4Gab cells restored cell surface co-localization of AJ components
(Figure 14D). In TSWTGsh and SUM159 cells having a near complete loss of GALNT3,
expression of d-catenin and a-catenin were significantly reduced (Figures 14D-14F).
Together, these data suggested that AJ assembly and stability in TS cells and HMECs are
GALNT3 dependent.
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Figure 14. GALNT3 regulates adherens junction assembly. (A) Western blots of TSWT
and TSKI4 cells infected with a control lentiviral construct (C) or TSKI4 cells infected with
a lentiviral construct expressing human Galnt3 (TSKI4Gab1 and TSKI4Gab2) are shown. (B)
Western blots of TSWT and TSKI4 cells infected with a control shRNA or TSKI4 cells
infected with Hdac6 shRNA (TSKI4H6sh) are shown. (C) Western blots of HMECs infected
with a control shRNA (C) or Galnt3 shRNAs (HMECGsh1 and HMECGsh2) are shown. (D)
Loss of GALNT3 in TSKI4 and TSWTGsh cells results in reduced co-localization of dcatenin and E-cadherin. DAPI (blue), E-cadherin (green) and d-catenin (red). Confocal
microscopy images are representative of three independent experiments. White bar
represents 50 µm. (E) Western blots of TSWT and TSKI4 cells infected with a control
shRNA or TSWT cells with Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2) are shown. (F)
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Figure 14 (Continued)
SUM159 cells lacking GALNT3 have reduced d-catenin, a-catenin and Vinculin protein
levels relative to HMEC cells as shown by Western blotting. (A-C and E-F) Western
blots are representative of three independent experiments. See also Figure S4.
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Reduced GALNT3 in TSKI4 cells results in dynamic adherens junction assembly
AJs can be classified as two main forms, linear or punctate, based on their
association with actin (Takeichi, 2014). TSWT cells displayed linear cortical actin
filaments that ran parallel to the cell borders forming static, linear AJs (Figures 15 and
S4A). In TSKI4 cells, actin stress fibers were positioned perpendicular to cell borders,
suggesting the presence of dynamic, punctate AJs (Figures 15 and S4A). Re-expression
of GALNT3 in TSKI4Gab cells restored cortical actin that ran parallel to the cell borders
(Figures 15 and S4A). AJs are often linked to the actin cytoskeleton through the actinbinding protein Vinculin (Takeichi, 2014). Total Vinculin expression did not change
significantly under any conditions tested (Figure 14). In TSWT cells, AJs contained small
Vinculin-positive puncta with larger Vinculin-positive adhesions positioned continuously
around the entire TSWT colony (Figures 15 and S4A). In TSKI4 and TSWTGsh cells,
Vinculin was present in discontinuous, finger-like projections (Figures 15 and S4A). Reexpression of GALNT3 in TSKI4Gab cells restored continuous Vinculin-positive adhesions
around the colony (Figures 15 and S4A). However, these Vinculin positive focal
adhesions were more finger-like than those found in TSWT colonies. Western blotting
showed that shRNA knockdown or re-expression of GALNT3 did not alter HDAC6
levels (Figures S4B-S4D). The retention of elevated HDAC6 expression in TSKI4Gab cells
may explain the retention of finger-like Vinculin projections. Altogether, these data
suggested that loss of GALNT3 leads to active remodeling and disassembly of AJs, and
GALNT3 re-expression promotes stable AJ assembly. Importantly, re-expression of
GALNT3 restores the localization of E-cadherin to the cell surface leading to stable
adherens junction assembly and maintenance of the epithelial state.
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Figure 15. GALNT3 promotes adherens junction assembly and maintenance.
Confocal images in TSWT and TSKI4 cells infected with a control virus, TSWT cells
infected with Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2), and TSKI4 cells expressing human
GALNT3 (TSKI4Gab1 and TSKI4Gab2) are shown. DAPI (blue), Actin (red) and Vinculin
(green). Arrows show the area of enlarged insets. Arrowheads indicate actin and vinculin
co-localization. Images are representative of three independent experiments. White bar
represents 50 µm. See also Figure S4.
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Discussion

Herein, we define a critical role of O-GalNAc glycosylation in epithelial TS cells
derived from the preimplantation blastocyst. We demonstrate that O-GalNAc
glycosylation of E-cadherin in TS cells is dependent on GALNT3. Loss of GALNT3
results in the retention of E-cadherin in the Golgi, disruption of AJs, and induction of
EMT. Importantly, re-expression of GALNT3 in mesenchymal-like TSKI4 cells restores
E-cadherin localization to the cell surface and the epithelial state. Our work defines a key
role for GALNT3 dependent O-GalNAc glycosylation in promoting the epithelial state in
TS cells and HMECs. This study is the first to identify the role of a specific O-GalNAc
glycosyltransferase in TS cells of the early blastocyst.
The role of O-GalNAc glycosylation in stem cells is poorly understood.
Unextended O-GalNAc modified proteins have been detected in early preimplantation
blastocysts, but the specific GALNT(s) that initiate this glycosylation were unknown
(Poirier and Kimber, 1997). Differentiation of mouse embryonic stem cells to embryoid
bodies or extraembryonic endoderm cells increases the expression of GALNTs, including
Galnt3. These findings suggest that O-GalNAc glycosyltransferases may play key roles
in early differentiation (Nairn et al., 2012). Here, we demonstrate GALNT3 dependent OGalNAc glycosylation on the cell surface of the TE of E3.5 blastocysts. Cell surface OGalNAc modified proteins are dramatically reduced in TSKI4 cells and TSWTGsh cells
lacking GALNT3 relative to TSWT cells. Total O-GalNAc glycosylation levels in TS cells
correlate with the absolute expression levels of GALNT3. For example, TSKI4 cells with a
70% decrease in GALNT3 show reduced total O-GalNAc glycosylation relative to TSWT
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cells. Further, >98% shRNA knockdown of GALNT3 in TSWT cells results in a complete
loss of total O-GalNAc glycosylation. In addition, loss of GALNT3 in blastocysts
decreases total O-GalNAc levels. Importantly, re-expression of GALNT3 in TSKI4 cells
increases total O-GalNAc glycosylation. Although GALNT3 strongly controls total OGalNAc glycosylation in TS cells, alterations in GALNT3 levels in pancreatic and
ovarian cancers result in more modest changes in total O-GalNAc glycosylation (Chugh
et al., 2016; Maupin et al., 2010; Wang et al., 2014). Together, these data demonstrate
that GALNT3 dependent O-GalNAc glycosylation maintains the epithelial TS cells of the
TE during early development.
E-cadherin is a transmembrane protein localized to AJs that mediates calcium
dependent adhesion. Loss of E-cadherin is a key step in EMT associated with tumor
progression and resistance to conventional drug therapies (Pattabiraman et al., 2016).
Previous studies have focused on the transcriptional regulation of E-cadherin. However,
the mechanisms regulating the folding and localization of E-cadherin are poorly
understood. Using mass spectrometry, Vester-Christensen et al. identified an O-GalNAc
site on the EC1 domain of E-cadherin, but the functionality of the site was undefined.
Our data show that a MAP3K4 dependent gene, Galnt3, regulates EMT by controlling
the O-GalNAc glycosylation of multiple proteins including E-cadherin and the
localization of E-cadherin. Differences in absolute levels of GALNT3 in TSKI4 cells and
TSWTGsh cells may result in a partial versus full EMT and differences in E-cadherin
levels. While O-GlcNAc and N-glycosylation of E-cadherin results in cytoplasmic
retention and disruption of AJs, we show that O-GalNAc modification of E-cadherin
correlates with cell surface localization and proper AJ assembly, including a and
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d catenin localization (Jamal et al., 2009; Zhu et al., 2001). Together, these data
demonstrate that GALNT3 promotes the epithelial TS cell phenotype in part by
mediating O-GalNAc modification of E-cadherin.
In summary, we define a post-translational mechanism of EMT regulation
through GALNT3 dependent O-GalNAc glycosylation of proteins including E-cadherin.
Importantly, GALNT3 regulates the localization AJ proteins, indicating that O-GalNAc
glycosylation promotes TS focal adhesion assembly. We predict that GALNT3 OGalNAc glycosylates additional targets that are important in regulating EMT in TS cells,
and future work will focus on identifying these targets. In addition, we detected Tn
antigens at the surface of wild-type TS cells and the TE of E3.5 blastocysts, suggesting a
possible role for unextended O-GalNAc glycosylation during early development. Further
investigation will determine the identity of O-GalNAc modified proteins and their roles
in early development. Together, our work provides insights into O-GalNAc glycosylation
events occurring during developmental EMT that may be reactivated during cancer
progression.
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Supplemental Figures

Figure S3. Decreased GalNAc modified proteins in TS cells and mammary epithelial
cells lacking GALNT3. Related to Figure 10. (A) Increased protein O-GalNAc
glycosylation with re-expression of GALNT3 in SUM159Gab cells. Immunoprecipitation
(IP) with VVL-agarose and blotting with biotinylated VVL is shown. Blots are
representative of two independent experiments. Arrowheads indicate differentially
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Figure S3 (Continued)
increased O-GalNAc modified proteins in SUM159Gab cells relative to control infected
SUM159 cells. (B) shRNA knockdown of GALNT3 in HMECs reduces total protein OGalNAc glycosylation. IP with VVL agarose beads and blotting with biotinylated VVL in
HMECs infected with control (C) or HMECs infected with Galnt3 shRNAs (HMECGsh1
and HMECGsh2) is shown. Blots are representative of three independent experiments. (C)
SUM159 cells lacking GALNT3 have reduced total protein O-GalNAc glycosylation
relative to HMECs. Experiments were performed as in (A). Blots are representative of
three independent experiments. (D) Decreased expression of GALNT3 correlates with
reduced VVL fluorescence intensity. Quantitation of VVL intensity is shown for TSWT
and TSKI4 cells infected with a control virus, TSWT cells infected with Galnt3 shRNA
(TSWTGsh), and TSKI4 cells re-expressing Galnt3 (TSKI4Gab). Data are expressed as a fold
change relative to TSWT cells and are the mean ± SEM of three independent experiments.
(E) Decreased expression of GALNT3 correlates with reduced numbers of VVL positive
cells. Data are expressed as the percent of cells that are VVL positive and are
representative of three independent experiments. (D, E) *p-value < 0.05, ***p-value <
0.001, not significant (n.s.), ANOVA test. (F) Immunofluorescence images of
biotinylated VVL staining of non-permeabilized E3.5 wild-type hatched blastocysts are
shown. Images were obtained using EVOS epifluorescence microscopy. Representative
images of seven blastocysts are shown. White bar represents 100 µm. (G) Intracellular
retention of O-GalNAc glycosylated proteins in cells lacking GALNT3.
Immunofluorescence staining with biotinylated VVL was performed on 0.1% Triton
treated cells. Epifluorescence images are representative of three independent
experiments. White bar represents 50 µm. (H) TSKI4Gab1 and TSKI4Gab2 cells re-expressing
GALNT3 express transcripts for other Galnts at levels similar to TSWT cells. qPCR data
for TSWT and TSKI4 cells infected with control shRNA or TSKI4 cells re-expressing Galnt3
(TSKI4Gab1 and TSKI4Gab2) are shown. (I) Transcript expression of other Galnts measured
by qPCR in TSWT and TSKI4 cells infected with control shRNA or TSWT cells infected
with Galnt3 shRNAs (TSWTGsh1 and TSWTGsh2) are shown. (H, I) qPCR data normalized to
Actb are expressed as a fold change relative to TSWT cells and are the mean ± range of
two independent experiments. *p-value < 0.05; ***p-value < 0.001, Student’s t test.
MW, Molecular weight in kDa
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Figure S4. Loss of co-localization of Actin and Vinculin in cells lacking GALNT3.
Related to Figure 15. (A) Confocal 3D images are shown for TSWT and TSKI4 cells
infected with a control virus, TSWT cells infected with Galnt3 shRNAs (TSWTGsh1 and
TSWTGsh2), and TSKI4 cells expressing human Galnt3 (TSKI4Gab1 and TSKI4Gab2). DAPI
(blue), Actin (red) and Vinculin (green). Images are representative of three independent
experiments. X, Y and Z axes represent the spatial resolution and field of view of the
image. Box represents the Voxel size that constitutes the X,Y pixel dimensions (512 X
512) with the section thickness that is represented by the z plane. White bar represents 50
µm. (B) Hdac6 transcripts analyzed by qPCR in TSWT and TSKI4 cells infected with a
control virus (C), TSWT cells infected with Galnt3 shRNA (TSWTGsh) and TS cells
expressing human Galnt3 (TSKI4Gab). qPCR data normalized to Actb are expressed as a
fold-change relative to TSWT cells and are mean ± SEM of two independent experiments.
***p-value < 0.001, Student’s t test. (C-D) Western blots for HDAC6 and a-tubulin are
shown. (C) Blots are representative of three independent experiments. (D) Densitometry
was used to quantify three independent experiments. Data normalized to a-tubulin
loading control are expressed as a fold change relative to TSWT cells and are the mean ±
SEM of three independent experiments. *p-value < 0.05, ***p-value < 0.001, not
significant (n.s.), ANOVA test.
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Chapter IV
Conclusion
We define a mechanism controlling the expression of GALNT3 and the role of
this enzyme in promoting the epithelial state. GALNT3 is abundantly expressed in both
epithelial TS cells and HMECs. Mesenchymal-like TSKI4 cells and CL breast cancer cells
have reduced GALNT3 expression, suggesting a correlation between GALNT3 levels
and the cellular states. shRNA knockdown of GALNT3 in epithelial TS cells induces a
mesenchymal state with a gain in EMT characteristics. Re-expression of GALNT3 in
TSKI4 cells restores the epithelial morphology, thus resulting in MET. GALNT3
expression is epigenetically inhibited by HDAC6 dependent deacetylation of the Galnt3
promoter. Inhibition of HDAC6 restores GALNT3 expression and the epithelial state. In
addition to controlling the epithelial state in cultured TS cells and HMECs, GALNT3
plays a critical role in regulating the cellular phenotype in the preimplantation blastocyst
TE. Loss of GALNT3 in the blastocyst TE results in early attachment and outgrowth,
inducing premature EMT. Together, these data suggest that GALNT3 is an important
regulator of cellular phenotypic states in the TS cells, blastocyst TE, and mammary cells.
GALNT3 belongs to a family of 19 functionally redundant GALNTs that initiate
O-GalNAc glycosylation. All GALNTs are expressed in the epithelial TS cells and
HMECs. shRNA knockdown of GALNT3 in the TS cells and HMECs results in a
complete loss of O-GalNAc glycosylation without altering the expression of other
GALNTs. This lack of compensation by other GALNTs suggests that GALNT3 is the
dominant O-GalNAc glycosyltransferase in TS cells and HMECs. In addition to reduced
O-GalNAc modification of proteins, loss of GALNT3 dependent O-GalNAc
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glycosylation results in protein mislocalization. We observe that GALNT3 initiates OGalNAc glycosylation of multiple proteins including E-cadherin in the epithelial TS cells
and HMECs. Reduced O-GalNAc glycosylation of E-cadherin results in the intracellular
retention of E-cadherin, thus inducing EMT. These data suggest that GALNT3 dependent
O-GalNAc modification of E-cadherin promotes in cell surface localization that is critical
for the maintenance of an epithelial state.
We predict that GALNT3 controls the O-GalNAc modification of multiple
proteins. The future goal of this project is to identify additional targets of GALNT3 and
to define their roles in EMT. We also observe O-GalNAc modified proteins in the TE of
the wild-type blastocyst, suggesting a possible role of these proteins in early
development. Future work will focus on identifying these proteins and examine their
roles in early developmental EMT. Altogether, our work provides new insights on the
role of O-GalNAc glycosylation in developmental EMT that is reactivated during cancer
metastasis.
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Appendix A
Antibodies
REAGENT or
RESOURCE
Alexa Fluor Phalloidin 594
Alexa Fluor 488conjugated Streptavidin
Donkey anti-mouse
peroxidase conjugate
Donkey anti-rabbit
peroxidase conjugate
Goat anti-mouse
polyclonal Daylight 488
Goat anti-rabbit polyclonal
Daylight 488
Mouse monoclonal antilClaudin-6
Mouse monoclonal anti-Ecadherin
Mouse monoclonal antiFlag
Mouse monoclonal antiGAPDH
Mouse monoclonal antiTubulin
Mouse monoclonal antiTubulin
Mouse monoclonal antiVinculin
Rabbit polyclonal Alexa
594
Rabbit monoclonal antiAlpha 1 catenin
Rabbit monoclonal antiDelta 1 catenin
Rabbit monoclonal anti-Ecadherin
Rabbit monoclonal antiH2BK5Ac
Rabbit monoclonal antiHDAC6

SOURCE

IDENTIFIER

Thermo Fisher Scientific

Cat#A12381; RRID:
AB_2315633
Cat#016-540-084; RRID:
AB_2337249
Cat#715-035-151; RRID:
AB_2340771
Cat#711-035-152; RRID:
AB_10015282
Cat#35503; RRID:
AB_1965946
Cat#35553; RRID:
AB_1965947
Cat#sc-393671

Jackson ImmunoResearch
Labs
Jackson ImmunoResearch
Labs
Jackson ImmunoResearch
Labs
Thermo Fisher Scientific
Thermo Fisher Scientific
Santa Cruz Biotechnology
BD Biosciences
Thermo Fisher Scientific
Thermo Fisher Scientific
Santa Cruz Biotechnology
Sigma-Aldrich
Abcam
Cell Signaling Technology
Abcam
Abcam
Abcam
Active Motif
Cell Signaling Technology
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Cat#610181; RRID:
AB_397580
Cat#MA1-91878; RRID:
AB_1957945
Cat#AM4300; RRID:
AB_2536381
Cat#sc-53646; RRID:
AB_630403
Cat#T6793; RRID:
AB_477585
Cat#ab18058; RRID:
AB_444215
Cat#8889; RRID:
AB_2716249
Cat#ab51032; RRID:
AB_868700
Cat#ab92514; RRID:
AB_10565040
Cat#ab212059
Cat#39123; RRID:
AB_2615079
Cat#7612; RRID:
AB_10889735

Antibodies (Continued)
REAGENT or
RESOURCE
Rabbit monoclonal antiIgG
Rabbit monoclonal antiLamin B1
Rabbit polyclonal antiERK2
Rabbit polyclonal antiGALNT3
Biotinylated Vicia Villosa
Lectin
Peroxidase-streptavidin

SOURCE

IDENTIFIER

Abcam

Cat#ab172730; RRID:
AB_2687931
Cat#ab133741; RRID:
AB_2616597
Cat#sc-154; RRID:
AB_2141292
Cat#AP9208C; RRID:
AB_10612485
Cat#B-1235; RRID:
AB_2336855
Cat#016-030-084; RRID:
AB_2337238

Abcam
Santa Cruz Biotechnology
Abgent
Vector Laboratories
Jackson ImmunoResearch
Labs
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Appendix B
Critical commercial assay
REAGENT or
RESOURCE
iTaq Universal SYBR
Green Supermix
Rneasy Plus Mini Kit
Rneasy Micro Kit
High capacity cDNA
Reverse Transcription Kit
Gateway LR Clonase II
Enzyme mix
Corning BioCoat Matrigel
Invasion Chamber: With
GFR Matrigel Matrix
SsoAdvanced Universal
SYBR Green Supermix
GeneJet Plasmid Miniprep
Kit
Transwells 6.4mm with
0.4µm pore polycarbonate
Transwells 6.4mm with
0.4µm pore polyethylene
terephthalate
Q5 Site-Directed
Mutagenesis Kit

SOURCE

IDENTIFIER

Bio-Rad

Cat#1725125

Qiagen
Qiagen
Thermo Fisher Scientific

Cat#74134
Cat#74004
Cat#4368813

Invitrogen

Cat#11791-020

Thermo Fisher Scientific

Cat#08-774-193

Bio-Rad

Cat#1725274

Thermo Fisher Scientific

Cat#K0502

Corning

Cat#3413

Corning

Cat#353095

New England BioLabs

Cat#E0554S
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Appendix C
Chemicals, Peptides and Recombinant Proteins
REAGENT or
RESOURCE
2-mercaptoethanol (BME)
Agarose bound Vicia
Villosa Lectin beads
Enzyme Free Cell
Dissociation Solution PBS
Based (1X)
Fetal Bovine Serum-Gibco
Hyclone Glutamine
Heparin
Hyclone PenicillinStreptomycin
Recombinant Human
FGF4
Recombinant Protein A
Sepharose 4B
Sodium pyruvate
Trypsin (0.05%)
Insulin, Human
Recombinant Zinc Solution

SOURCE

IDENTIFIER

Thermo Fisher Scientific
Vector Laboratories

Cat#31350010
Cat#AL-1233; RRID:
AB_2336854
Cat#S-014-C

Millipore Sigma
Thermo Fisher Scientific
Thermo Fisher Scientific
Sigma-Aldrich
Thermo Fisher Scientific

Cat#10437-028
Cat#SH3003401
Cat#H3149-10KU; CAS:
9041-08-1
Cat#SV30010

Peprotech

Cat#100-31

Thermo Fisher Scientific

Cat#101141

Thermo Fisher Scientific
Thermo Fisher Scientific
Thermo Fisher Scientific

Cat#SH30239.01
Cat#SH30236.01
Cat#12585014

115

Appendix D
Plasmids
REAGENT or
RESOURCE
Mouse Galnt3 shRNA
(Gsh1)
Mouse Galnt3 shRNA
(Gsh2)
Human Galnt3 shRNA
(Gsh1)
Human Galnt3 shRNA
(Gsh2)
Entry Vector Human
Galnt3

SOURCE

IDENTIFIER

Open Biosystems

TRCN0000055098

Open Biosystems

TRCN0000055099

Dharmacon

TRCN0000035456

Dharmacon

TRCN0000035458

Vidal Human ORFeome
(Version 5.1)

Clone# 55179 BCII3565 in
pDONR223
Addgene
Plasmid#49776; RRID:
Addgene_49776

pENTR-Cdh1

(Cachat et al., 2014)

Lentiviral FLAG tagged
destination vector

Kind Gift from Dr. Gary
Johnson
(Jordan et al., 2013)
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Appendix E
Primers for Real-time quantitation PCR for mRNA
Gene Name
Actb
mouse
Cdh1
mouse
Cdh2
mouse
Cdx2
mouse
Csh1
mouse
Eomes
mouse
Esrrb
mouse
Ets2
mouse
Fgfr2
mouse
Galnt1
mouse

Forward Primer
AGC CAT GTA CGT AGC CAT
CC
CAG GTC TCC TCA TGG CTT
TGC
AGC GCA GTC TTA CCG AAG
G
AAG CCA AGT GAA AAC CAG
GAC A
TTA TCT TGG CCG CAG ATG
TG
GCG CAT GTT TCC TTT CTT
GAG
GGA CTC GCC GCC TAT GTT C
CCT GTC GCC AAC AGT TTT
CG
GCC TCT CGA ACA GTA TTC
TCC T
TCC TGC TGC TTT ACT TCA
GTG

Reverse Primer
CTC TCA GCT GTG GTG
GTG AA
CTT CCG AAA AGA AGG
CTG TCC
TCG CTG CTT TCA TAC TGA
ACT TT
GGC AGC CAG CTC ACT
TTT C
TCT GTC TGT TAT CCA AGT
TTT ATC GAA
GGT CGG CCA GAA CCA
CTT C
CGT TAA GCA TGT ACT
CGC ATT TG
TGG AGT GTC TGA TCT
TCA CTG A
ACA GGG TTC ATA AGG
CAT GGG
GAC GAC TGG TTT CCC
CAT TTC

Galnt2
mouse
Galnt3
mouse
Galnt3
human

GGA GAT GAG AAA GCA CAG
GGT
TGC AAA TAG GAG CGC CCA
TTA
AGC GTT GGT CAG CCT CTA
TG

TGC CTC CTG GTT AAA
GTC TGG
GGC GAT CAA AAA CCG
GCT TC
TCC TTC TGG ATG TTG TGC
CG

Galnt4
mouse

CGG TCA AGG AGG CAA TCA
GT

CCG TCT TTG GGG CAG
TTT TG

Galnt6
mouse

AGG RGC TGT GAA CAA CAT
TAG G

CCC AGA AGG GTT TCA
GCT CAG

Galnt7
mouse
Galnt10
mouse

TAT GCT CCA CTT GTA GCC
CC
AAG GAG GCT ATC AGG AGG
GAC

CCC CTC TGG CAA AAC
CAT CT
AGA GAG CGA TTC AGG
GAG ATT
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Primers for Real-time quantitation PCR for mRNA (Continued)
Gene Name
Galnt11
mouse
Galnt12
mouse
Gcm1
mouse
Hdac6
mouse
Krt8
mouse
Krt18
mouse
Pac
mouse
Prl2C2
mouse
Snai1
mouse
Snai2
mouse
Tbp
human
Tpbpa
mouse
Twist 1
mouse
Vim
mouse
Zeb1
mouse

Forward Primer
GTG ACT CAG CCC CTT
AGG AAT
TGT GGT GGC ACT CTG
GAA AC
AGA GAT ACT GAG CTG
GGA CAT T
TCC ACC GGC CAA GAT
TCT TC
CGG CTA CTC AGG AGG
ACT GA
GTG GAT GCC CCC AAA
TCT CA
TGA CCG AGT ACA AGC
CCA C
TCA ACC ATG CTC GTC
GAT ACT G
CAC ACG CTG CCT TGT
GTC T
TGG TCA AGA AAC ATT
TCA ACG CC
GAG AGT TCT GGG ATT
GTA CCG
TTC CTA GTC ATC CTA
TGC CTG G
GGA CAA GCT GAG CAA
GAT TCA
TCC ACA CGC ACC TAC
AGT CT
ACC GCC GTC ATT TAT
CCT GAG

Reverse Primer
CTG TGG ATC TAA TAC CCG
ACC T
CGG GAA TAG GGA GCT TGC
TT
CTG TCG TCC GAG CTG TAG
ATG
CAG CAC ACT TCT TTC CAC
CAC
TGA AAG TGT TGG ATC CCC
CG
CCT CAA TCT GCT GAG ACC
AGT
ACA CCT TGC CGA TGT CGA
G
GGC AAC ATT CTT CCA CAA
TAA G
GGT CAG CAA AAG CAC GGT
T
GGT GAG GAT CTC TGG TTT
TGG TA
ATC CTC ATG ATT ACC GCA
GC
GGT CAT TTT CGC TAC TGT
GAA GT
CGG AGA AGG CGT AGC TGA
G
CCG AGG ACC GGG TCA CAT
A
CAT CTG GTG TTC CGT TTT
CAT CA

Primers for ChIP coupled to Real-time quantitative PCR
Gene Name
Cldn7
Human
Galnt3
mouse
Human
Galnt3

Forward Primer
AAG AAA CCT GAG CAC
CAG GG
CTC GGG GCA AAC TCA TCT
GT
GCT TGG TGC AGT AAT TTT
TTT CTTT
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Reverse Primer
CGG TGT TCG AGG GAA ATC
CA
AGG TGA CGC TTT CCA AAC
CA
TTT CCA TCC TTG ATT CCT
CTT TG

Primers for ChIP coupled to Real-time quantitative PCR
Gene Name
Krt19
Human

Forward Primer
AAG CTA ACC ATG CAG
AAC CTC AA

Reverse Primer
CAG GGC GCG CAC CTT

Primers for Site Directed Mutagenesis
Gene Name
Cdh1 mouse
T40A
Cdh1
mouse
T63A
Cdh1
mouse
T68A

Forward Primer
CGA GGT CTA CGC CTT
CCC GGT
TGA AGG ATG CGC TGG
CCG GCC

Reverse Primer
GAA CTG AAG CCG GGA CTG

CCG GCC AAG GGC AGC
CTT CTT

CCA GTG CAT CCT TCA AAT
CTC ACT C

AAT CTC ACT CTG CCC AGG
ACA TGG

Primer for Sequencing
Gene Name
Cdh1 sequencing
primer

Forward Primer
CAG GTC TCC TCA TGG CTT TGC
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